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Summary 
 
Hepatocellular carcinoma (HCC), or the cancer of the liver, is of great concern due to its 
poor patient outcome despite the various treatments available. It is imperative, therefore, 
that a novel, viable treatment method is developed such that patient survival rates may be 
improved from current statistics of less than 50%. The role of miRNAs in the regulation 
of gene expression and cellular development makes it an important player in cancer 
development process, as it is found that the aberrant expression of miRNAs is a typical 
feature of cancer cells or even pre-disposed cancer cells. MiR-181a has been shown to be 
an important miRNA involved in HCC. In this study, we investigated the potential effects 
of miR-181a in HepG2 cells and the mechanisms in which it works in controlling cell fate. 
As chemotherapy is widely used in liver cancer treatment, we also study the use of miR-
181a along with chemotherapy (i.e. Cisplatin). Using iTRAQ-coupled 2D LC-MS/MS 
analysis, we report here the study of protein profile of HepG2 cells transfected with miR-
181a and its inhibitor respectively. Three main types of cellular proteins including 
metabolic enzymes, protein binding and stress proteins displayed changes. The changes in 
the level of proteins (14-3-3σ, Hsp-90β and NPM1) involved in important cancer 
processes like cell growth were further supported by a Western blot analysis. MiR-181a 
was subsequently found to significantly increase HepG2 cell viability while inhibiting it 
displayed the opposite effect. Inhibiting miR-181a also sensitized HepG2 cells to cisplatin 
treatment and retards cell cycle progression by decreasing the proportion of cells in S and 
G2/M phases.  
We next investigated the reasons behind these observations at a molecular level. As 
miRNAs are known to regulate genes by binding to and targeting mRNAs, we first used 
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bioinformatics to screen out potential cellular targets. Two important genes identified, 
cyclin-dependent kinase inhibitor 1B (CDKN1β) and transcriptional factor E2F7 (E2F7), 
which are involved in cell cycle and cell proliferation, were chosen to be further 
experimentally studied. In vitro validation via surface plasmon resonance (SPR) technique 
showed a positive binding between miR-181a and the seed regions of the 3’UTRs of the 
two putative mRNA targets, with dissociation constants being 272.5 ± 0.008 nM and 
1.186 ± 0.009
 
uM for CDKN1β and E2F7 respectively. In vivo luciferase assay studies 
further validated the miR-181a:mRNA bindings, in both cases displaying significant 
decrease in luciferase activity when HepG2 cells were co-transfected with the 3’UTR-
containing reporter plasmids and miR-181a.  A positive binding, however, may not 
necessarily lead to a lowered expression of protein levels. A Western blot study on the 
expression levels of the two proteins, however, showed a decrease in the levels of 
CDKN1β and E2F7.  
Lastly, to gain an insight into the overall effects miR-181a has in HepG2 cells, a 
microarray analysis was performed. Cellular pathways important in cancer were studied 
and results show that miR-181a significantly activated the MAPK/JNK pathway by 
increasing the expression levels or activity of transcription factor activator protein 1 (AP-
1). Inhibiting miR-181a, on the other hand, abolished this observation and significantly 
decreased expression levels or activity of hypoxia-inducible factors (HIF) and also 
significantly upregulated the expression levels or activity of SMAD2/3/4 proteins, 
possibly inducing a cancer-suppressing effect. Overall, miR-181a appears to activate 
mainly cancer-promoting pathways, and may act as an oncogene in HepG2 cells. 
Inhibiting it, on the other hand, activates mainly the tumour-suppressing pathways, 
18 
 
making it a possible option for therapy. A separate microarray analysis on gene 
expression showed that one way in which miR-181a could have activated the SMAD, 
NFκB and MAPK pathways is via the significant increase in gene expression of bone 
morphogenetic protein receptor type II (BMPR2), a cellular receptor that mediates the 
signal transduction of these pathways.  
Our findings provide a new platform of identifying miRNA targets, in the process offering 
molecular evidence on the mechanism of action of miR-181a, including the beneficial 
effects of inhibiting miR-181a in HCC therapy.
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1. Introduction 
 
1.1. Hepatocellular Carcinoma 
 
Hepatocellular carcinoma (HCC) is a primary malignancy of the liver and is known to be 
the fifth most common cancer worldwide today. It is also the third leading cause of 
cancer-related deaths, claiming more than 500,000 lives and affecting another 500,000 
new patients yearly [1]. HCC usually develops with liver cirrhosis, which may be caused 
by Hepatitis B virus (HBV) or Hepatitis C virus (HCV) infection, excessive consumption 
of alcohol or hemochromatosis. HCC comes with poor prognosis despite the many 
treatments available nowadays like chemotherapy, liver transplantation, surgical resection, 
transarterial chemoembolization (TACE) and hormonal therapy [2]. Most of these 
treatment options have relatively low survival rates of less than 50%, and patients do 
develop recurrences or second primary tumours. The reason as to why the effectiveness of 
these treatments is low may be attributed to the complicated nature of the disease. HCC is 
a disease of heterogeneous etiology and takes on various disease progression pathways 
after the onset of liver cirrhosis. Liver cirrhosis may lead to portal hypertension with 
hyper-splenism, platelet
 
sequestration, varices and gastrointestinal bleeding, hepatic
 
encephalopathy, hypoalbuminemia, differential drug binding and
 
distribution, and altered 
pharmacokinetics. These complications restrict the use of many cytotoxic compounds 
available for targeting the cancerous cells [3]. In addition, HCC tumours express the 
multi-drug resistant gene MDR-1 [4], rendering drug-related treatments to be ineffective.  
20 
 
However, a general consensus of cancer is that it may originate from a genetic mutation or 
from an epigenetic cause like DNA methylation or histone covalent modification [5]. In 
either case, the result would be an abnormality in the expression of both coding and non-
coding genes. More specifically, cancers result from the alterations in oncogenes, tumour-
suppressor genes and microRNA (miRNA) genes [6]. Usually more than one such gene 
alteration would be required to transform a normal cell into a cancer cell, which would 
mean that cancer cells contain aberrant genetic and proteomic profiles, deviating from its 
normal, healthy cell counterpart. Therefore, in order to effectively target cancer cells, the 
use of therapy that controls the level of aberrant genes, preferably to a level on par with 
that of normal cells, could possibly restore the state of the cancer cells to that of normal 
cells. This brings us to the study of miRNAs as a possible, potential target in cancer 
therapy. Figure 1 illustrates the transformation of a healthy mice liver into malignancy.  
As aforementioned, due to its heterogeneous nature, HCC is a complicated type of cancer 
that could, and perhaps should, be represented by many types of in vitro cell line models. 
In this project, we have chosen the HepG2 human liver carcinoma cell line to be used to 
exemplify HCC. HepG2 is a perpetual cell line of well-differentiated HCC, and is a type 
of epithelial cell that is able to secrete many plasma proteins, not unlike the liver itself. 
One reason why we have chosen to use this particular cell line is because it has been 
shown to be very comparable to primary hepatocytes, and therefore is a suitable candidate 
in our studies [7]. Furthermore, as we are mainly interested in the characterizing and 
understanding of the potential effects of miRNAs in HCC, we will simplify our studies in 
this case to focus on a single cell line in an attempt to minimize complications arising 
from this type of cancer. This way, we are able to get a more in depth understanding of 
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the potential mechanisms of our chosen miRNA in our study. Notwithstanding this 
simplification, similar work in the future on other HCC-derived cell lines could be done 
such that a more comprehensive study on the effects of miRNAs in HCC may be 
elucidated. 
 
Figure 1. PDGF-C Tg mice develop HCC. As PDGF-C Tg mice age, their livers become enlarged (A) and show a 
variety of pathologies, including HCC (black arrow), angiogenesis (white arrow head), and multilocular pseudocysts 
(speckled arrows). A liver from a WT littermate is shown (Left). Tg mice develop dysplastic foci or foci of altered 
hepatocytes by 6 months (B), and carcinomas are seen in 12-month-old mice (C). Note the loss of sinusoidal spaces and 
pseudogland formation in C. Original magnification in B and C is ×100 [8]. Copyright (2013) National Academy of 
Sciences, U.S.A. (Permission from ref.7 was obtained from publisher to use this figure). 
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1.2 MiRNA Biogenesis 
 
Figure 2 illustrates the biogenesis of miRNAs and their regulatory function in cells. 
 
Figure 2. MicroRNA biogenesis and function. RNA polymerase II transcribes the miRNA gene into a pri-miRNA in 
the nucleus. The pri-miRNA is processed into pre-miRNA by Drosha, which is then exported into the cytoplasm by 
Ran-GTP cofactor and Exp-5.  Dicer and TRBP cleave the miRNA duplex from the pre-miRNA, while helicase 
unwinds the mature miRNA duplex. One of the strands of the mature miRNA is subsequently incorporated into the 
miRISC, mediating the degradation or translational inhibition of the target mRNAs [9]. (Permission from ref.8 was 
obtained from publisher to use this figure). 
 
Pri-miRNA 
Most miRNA genes are located in the intergenic regions of the DNA [10] while some 
others are found in the introns or even in exons of DNA. MiRNA biogenesis begins with 
the transcription of the miRNA genes by RNA polymerase II (Pol II) at the promoter 
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regions [11, 12] in the nucleus, resulting in the formation of a long primary miRNA (pri-
miRNA) transcript that contains a fold-back structure with a stem loop between flanking 
segments of nucleotides [13]. Similar to mRNAs, this pri-miRNA transcript possesses the 
7-methylguanosine cap and a poly (A) tail [13, 14], but these are eventually removed 
during miRNA processing. 
Pri-miRNA to pre-miRNA 
After the pri-miRNA is formed, it is processed by a microprocessor complex made up of 
Drosha, an RNase III enzyme, and DiGeorge syndrome critical region gene 8 (DGCR8), a 
double-stranded RNA-binding domain protein, into 70-80 nucleotide long pre-miRNAs 
[15, 16] that consists of an imperfect stem-loop structure. This process is known as 
cropping, where the stem loop structure of pri-miRNAs is cleaved, producing a pre-
miRNA hairpin with two nucleotide 3’ overhangs. This cleavage by Drosha at a specific 
site of the pri-miRNA depends on the terminal loop size, stem structure, and the flanking 
sequence of the cleavage site because any change at these sites significantly decreases or 
entirely stops the Drosha processing of pri-miRNAs [17, 18]. The precision of this 
cleavage is very important in miRNA maturation. A shift in a single nucleotide on the pri-
miRNA will subsequently affect Dicer cleavage, and this could result in different 5’ and 3’ 
ends in the mature miRNA. This may reverse the relative stability of the original guide 
strand and its associated passenger strand, thereby incorporating the wrong mature strand 
into the RNA-induced silencing complex (RISC) for silencing of target mRNA. Even if 
the correct mature miRNA strand is incorporated into the RISC, the shift in its 5’-end will 
change the position of the seed sequence of the target mRNA, thus targeting the wrong 
mRNA altogether [19].  
24 
 
Pre-miRNA export to cell cytoplasm 
The pre-miRNA is exported out of the nucleus and into the cytoplasm by exportin-5 (Exp-
5) in the presence of Ran-GTP as a cofactor [20-22]. Exp-5 belongs to the karyopherin 
family of nucleocytoplasmic transport factors, and its association with Ran-GTP aids in 
the specific binding of the pre-miRNA in the nucleus and its export to the surrounding 
cytoplasm [23]. It has been reported that Exp-5 is able to identify the ‘minihelix motif’ of 
pre-miRNAs. This translocation process involves the hydrolysis of GTP to GDP by the 
cytoplasmic Ran GTPase-activating protein [24]. 
Pre-miRNA to mature miRNA 
In the cytoplasm, the pre-miRNA is processed into a ~22 nucleotide duplex miRNA by 
the RNase III enzyme, Dicer. Dicer is an ATP-dependent multidomain enzyme that 
cleaves both double-stranded siRNAs and miRNAs. Unlike Drosha, the mechanism of 
identification of its substrate pre-miRNA is not known [25]. The result of Dicer cleavage 
is a duplex with the mature miRNA in one of the strands of the stem loop, while the other 
strand contains its imperfectly paired passenger strand. Imperfectly paired, because both 
arms of the duplex contain G:U wobble pairs and single nucleotide insertions. These, in 
turn, cause one strand of the duplex to be less stable at its 5’-end [19].  Dicer binds with 
high affinity to the ends of dsRNAs with two nucleotide 3’-overhangs, resulting in the 
unwinding of the duplex. The unwinding of the duplex starts off at the end with lower 
thermodynamic stability, resulting in two ssRNA strands with different relative stabilities 
at their 5’-terminus. A general rule is that the strand with lower thermodynamic stability 
at this terminus is selected to be the mature strand (guide strand) while the other 
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(passenger strand) is degraded. In rare cases where both stands have similar 5’-end 
stability, each of the two strands are incorporated into the RISC at similar frequencies [26].  
1.3 Mature miRNA and mRNA Targeting 
 
Once the mature miRNA is selected, it is loaded into the RISC, which contains argonaute 
(AGO) proteins that form the core component of the RISC. There are eight AGO 
homologs reported in humans [27] and in particular, AGO2-associated RISCs have been 
reported to be involved in the cleavage of mRNA targets [28, 29]. AGOs contain two 
main domains – PAZ (Piwi/Argonaute/Zwille) and PIWI, both of which are important in 
miRNA processing. The PAZ domain binds to the 3’-end of the mature miRNA, probably 
by recognition of the 3’-overhangs. The PIWI domain is reported to possess slicer activity 
based on mutagenesis studies [28].  
The recognition of the mRNA target by the RISC is based on the nucleotide sequence 
complementarity between the loaded miRNA and the target. In humans, miRNAs bind 
with imperfect complementarity to its target mRNAs, although nucleotides 2-8 of the 
miRNA (the ‘seed region’) do often match very closely to the mRNA target. The degree 
of complementarity will decide whether the mRNA undergoes endonucleolytic cleavage 
or translational repression. Most of the time, in humans, miRNAs target their 
corresponding mRNAs via translational repression rather than mRNA cleavage. MiR-196 
is an example of a special case where its mRNA target Hoxb8 is cleaved [30].  
MiRNAs regulate translational activities by mediating pre-translational, co-translational 
or post-translational gene silencing. In eukaryotic cells, the initiation of translation begins 
with the recognition of the 5’-terminal cap of the mRNA by the eIF4E subunit of the 
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eukaryotic translation initiation factor (eIF), eIF4F and eIF4G. The association of eIF4G 
with eIF4E and polyadenylate-binding protein 1 starts off the translation process [31]. 
Where miRNA represses translation, AGO2 and related proteins may compete with the 
eIF4E for the 5’-terminal cap for binding, therefore preventing the translation of mRNAs 
[32].  MiRISCs are also reported to increase co-translational degradation of nascent 
proteins, reduce the elongation rate of the translation process and to increase the rate of 
mRNA deadenylation [33-37]. All these act to repress the translation of mRNAs into 
proteins.  
Following translational repression, mRNAs accumulate in processing bodies (P-bodies) of 
the cytoplasm. P-bodies include Dcp1p/Dcp2p, the activators of decapping, Dhh1p, Pat1p, 
Lsm1-7p, Edc3p and the 5’-3’-exonuclease Xrn1p [38-41]. It is in P-bodies that mRNAs 
are degraded, firstly by the shortening of the 3’-poly(A) tail, which then becomes the 
substrate for the decapping complex to remove its 5’-cap structure. Lastly, the transcript is 
degraded by the 5’-3’-exonuclease [42, 43]. There have been studies done that show that 
approximately 20% of let-7-repressed reporter mRNAs and 20% of fluorescently labelled 
microinjected let-7 miRNA co-localized in P-bodies [33, 34].  This may mean that the 
RISC complex directs the translationally repressed mRNAs into P-bodies for degradation 
or temporary storage away from any translation machinery, and this process is miRNA-
dependent [44]. Sometimes, the targeted mRNA is stored in P-bodies and later released 
back into the cytoplasm to be translated (ie. Delayed translation). These illustrate the 
importance of miRNAs in the regulation of cellular activities via the control of the 
translation of mRNAs.  
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1.4 Use of miRNAs in Cancer Therapy (RNA Interference) 
 
RNA interference has shown to be a potential method for use in cancer therapy, where 
oncogenes are targeted for knockdown. The use of small interfering RNAs (siRNAs) has 
been successful in performing this as compared to using double-stranded RNAs (dsRNAs) 
due to the evoking of the interferon response by longer exogenous RNA strands. siRNAs 
and miRNAs are essentially very similar, and they both employ Dicer enzyme and 
argonaute proteins in their biogenesis and silencing, respectively. Their origins differ 
slightly; miRNAs are thought to be endogenously expressed for various cellular purposes 
while siRNAs are viewed as exogenous compounds, for example, from viruses, 
transposons or transgene trigger. Their pre-cursors are also slightly different, where those 
of miRNAs being incompletely double-stranded while those of siRNAs are fully 
complementary dsRNAs. Functionally, they both are involved in gene knockdown, but 
with a slight difference in their effects. siRNAs are thought to bind with a higher level of 
complementarity as compared to miRNAs to their mRNA targets, and that they are 
somewhat more specific than miRNAs, although both are prone to produce off-target 
effects [45]. The higher the level of complementarity, the higher the chances of mRNA 
target degradation. Therefore, siRNAs typically control gene expression by causing a 
cleavage of mRNA targets while miRNAs mainly act by repression the translation of 
mRNAs into their proteins. Either way, they both generally lead to the inhibition of gene 
expression. The use of miRNAs will be further discussed.      
miRNAs form a subclass of small RNAs and are single-stranded, non-coding RNAs of 
19-25 nucleotides in length, originating from its precursor endogenous hairpin-shaped 
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transcripts [46]. Up to now, 2578 mature human miRNAs have been documented in the 
Sanger miRBase sequence database and more are expected to be identified [47]. Other 
subclasses of small RNAs include siRNAs, repeat associated small interfering RNAs [48], 
small nuclear RNAs, small nucleolar RNAs, Piwi-interating RNAs [49] and transacting 
short interfering RNAs [50]. Among these, miRNAs have recently been the spotlight of 
cancer research ever since they have shown to possess a functional role in humans. They 
have a diverse set of functions and are involved in various physiologically important 
processes in the body such as cellular proliferation, differentiation, cell cycle regulation, 
angiogenesis, metabolism, regulation of immune response and apoptosis [51, 52]. The fact 
that miRNAs are able to affect these important processes implies their significance in 
maintaining the integrity of a cell. One reason why miRNAs are able to possess so many 
vastly different functions is because they have a “one hit, multiple targets” property. This 
means that a single miRNA is able to negatively regulate multiple target proteins through 
direct interaction with the mRNAs. Conversely, a single mRNA gene is influenced by 
many different types of miRNAs. Approximately 3% of the entire human genome encodes 
for miRNAs and they regulate up to 30% of human protein coding genes [53].  
As miRNAs are able to regulate a large number of proteins, their aberrant expression 
disrupts the normal functioning of the cell, either by activating oncogenes or deactivating 
tumour suppressor networks. miRNAs, when overexpressed or upregulated in cancer cells, 
are considered to be oncogenes and have anti-apoptotic activity while those that are 
underexpressed or downregulated are considered to be tumour suppressors and have pro-
apoptotic activity.  These various upregulations and downregulations of different miRNAs 
contribute to the initiation and progression of many cancers in humans [54-57]. Currently, 
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many miRNAs have been identified and correlated with various cancers, and many of 
them are expressed exclusively in certain tissue types. Studies show that miRNA profiling 
in neoplasms provides an even higher accuracy for tumour diagnosis as compared to 
mRNA profiling [58]. Not only that, but miRNA signatures have also been shown to 
correlate with the extent of histological tumour differentiation in HCCs [59]. This could 
potentially mean that the use of miRNA profiles may help determine the degree of disease 
progression, the site of disease origin, and may also provide a platform for new and more 
effective treatment methods of cancer [60]. Table 1 shows several miRNA signatures in 
various types of cancers.  
Table 1. Cancer-related miRNAs [52]. (Permission from ref.51 was obtained from publisher to use this figure). 
 
As described above, cancer cells typically involve alterations of miRNAs or miRNA 
pathways. Therefore, by normalizing or correcting the miRNA expression levels to that of 
normal, healthy cellular levels, it could result in (i) the recovery of a normal cellular 
phenotype from a cancerous state; (ii) increased tumour differentiation; (iii) induction of 
tumour death; and/or (iv) prevention of metastasis. This correction of miRNA expression 
levels could either refer to an introduction of downregulated miRNAs or an inhibition of 
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upregulated miRNAs, both potentially resulting in restoring the miRNA levels to that of 
normal, healthy cells.  
1.4.1 miRNA Mimic Therapy 
 
The decreased expression of certain miRNAs in cancer cells that serve as tumour 
suppressors contributes to oncogene activation. mRNAs that were originally 
translationally repressed by these miRNAs will be more abundant and are translated into 
proteins that encourage growth and proliferation of cancer cells. A therapeutic approach 
may be to increase the expression of these repressed miRNAs using synthetic miRNA 
mimics. These mimics may be unstable, or only have a transient effect in cells. Hence, for 
sustained effect of the miRNAs in cancer cells, vector-based miRNA expression may be 
used to produce stably expressed miRNAs. MiRNA mimic therapy has been applied 
successfully by Takamizawa et al.[61], where they designed expression constructs to 
synthesize the mature miRNAs of two Let-7 isoforms (Let-7a and Let-7f) and introduced 
them separately into A549 adenocarcinoma cell line. Results from their experiments show 
a 78.6% reduction in the number of colonies. Another batch of similar experiments carried 
out on lung cancer cell lines show enhanced lung cancer cell radio-sensitivity [62], altered 
cell cycle progression and reduced cell division [63]. Other than this group of researchers, 
there have been many other groups reported to have successfully used miRNA mimics to 
repress cancer proliferation of various cell lines. Liang et al. [64] used a miR-155-based 
BLOCK-iT
TM
 Pol II miR RNAi expression vector in MDA-MB-231 breast cancer cells 
that silences CXCR4, resulting in the reduction of migration and invasion in vitro. They 
also found that mice injected with CXCR4 miRNA-expressing breast cancer cells 
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developed fewer lung metastases within one month than those injected with breast cancer 
cells without the miRNA. It has been thought that the CXCR4/SDF1/AKT pathway, 
which is a pathway that takes part in the invasion and metastasis of breast cancer cells, 
had been inhibited by the increase in miR-155 expression.  These independent studies 
show that an artificial introduction of underexpressed miRNAs in malignant cells is a 
potential therapeutic method in the treatment of cancer. 
1.4.2 Anti-miRNA Therapy  
 
Contrary to the miRNA mimic therapy, the overexpression of another subgroup of 
miRNAs in malignant cells requires an anti-miRNA therapy. These overexpressed 
miRNAs act as oncogenes themselves. Therefore, an introduction of synthetic antisense 
oligonucleotides complementary to the overexpressed, endogenous miRNAs or their 
precursors may result in their pairing with the miRNAs, occupying their binding sites and 
leaving their target mRNA in the unbound state [65]. There are three commonly used anti-
miRNA oligonucleotides (AMOs): (i) 2’-O-methyl AMOs; (ii) 2’-O-methoxyethyl AMOs 
and (iii) locked nucleic acid AMOs. These modified RNA oligos are known to have a 
greater stability and have a delayed clearance following systemic administration [66], and 
their most important property is their specificity and high binding affinity for RNA. Anti-
miRNA therapy has been used in the knockdown of oncogene miR-21. In those studies, 
the use of 2’-O-methyl- and/or DNA/LNA-mixed oligonucleotides to inhibit miR-21 in 
glioblastoma and breast cancer cells suppressed cell growth due to the increase in pro-
apoptosis caspase activity [67, 68]. Not only that, but the inhibition of miR-21 also 
significantly reduced invasion and lung metastasis in MDA-MB-231 metastatic breast 
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cancer cells [69], RKO human colon cancer cells [70], and glioblastoma cells [71]. Figure 
3 illustrates the interference in the miRNA pathway by modified antisense synthetic 
oligonucleotides. 
 
Figure 3. Interference in the miRNA pathway by modified antisense synthetic oligonucleotides. Inhibition of 
miRNA can be achieved by introducing antisense synthetic oligonucleotides against miRNAs in the cytoplasm (shown 
as continuous lines). The possible targets of antisense synthetic oligonucleotides against miRNAs in the nucleus are pri-
miRNA and pre-miRNA (shown as dotted lines) [9]. (Permission from ref.8 was obtained from publisher to use this 
figure). 
 
1.5 MicroRNAs in Hepatocellular Carcinoma 
 
The development of hepatocellular tumour is known to be a multi-step process that 
involves several structural and genomic alterations such that many subsequent pathways 
are affected [60, 72]. The changes in miRNA expression levels occur early during 
hepatocarcinogenesis. Even before the onset of HCC (ie. During liver cirrhosis and other 
pre-malignant lesions [73]), these changes may already be detected and therefore, it 
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remains an exciting possibility that miRNAs could actually act as early warning markers 
for liver cancer initiation or progression. This has been demonstrated in the case of miR-
145 and miR-198, where their downregulation in cirrhotic tissue has been observed, 
followed by their further downregulation in HCCs of increasing histological grades [74]. 
This has also been shown to take place in other cancer-affected organ sites like in the 
colons [75] and the thyroid [76].  
Thus far, many studies on miRNAs and their profiles in HCC have been done by many 
different groups of researchers. The geographical origins of patients involved varied from 
the USA, Italy, Japan, France, Germany, China and Singapore. The predisposing risk 
factors and etiologies of HCCs in those studies were inhomogeneous, and the methods 
used in the studies varied. Therefore, even though many hundreds of precursor and mature 
miRNAs have been studied, only limited overlaps exists between the results of 
overexpressed and underexpressed miRNAs in HCCs. Table 2 shows the miRNAs that are 
found to be dysregulated by more than one group of researchers and are therefore more 
likely to be of significance in hepatocellular carcinogenesis.  
Table 2. Frequently dysregulated microRNAs in hepatocellular carcinomas [77]. (Permission from ref.76 was 
obtained from publisher to use this figure). 
miRNA Location Dysregulation Suggested Targets 
miR-122a 18q21.3 Decreased Cyclin G1, CAT1, 
EDN1, VAV3, GYS1  
miR-125a 19q13.3 Decreased TIMP3, 
FAK,VEGF,EDN1 
miR-139 7p22.1 Decreased CTNNB1 
miR-150 9p24.3 Decreased MYB 
miR-145 5q32 Decreased MAP3K, MAP4K4, 
PXN 
miR-199a 1q24.3 Decreased KRAS, CASP2, 
TIMP3, Fibronectin 
miR-200b 1p36.33 Decreased PTPN12, ZFHX1B 
miR-214 9p24.3 Decreased BCL2L11, PTEN 
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miR-223  Decreased HLF, C/EBPα 
let-7a 22q13.3 Increased RAS, NF2 
miR-21 17q23.2 Increased PTEN, RECK, TIMP3 
miR-221 Xp11.3 Increased FAT2, c-Kit 
miR-222 Xq11.3 Increased FAT2, c-Kit 
miR-224 Xq28.3 Increased API5 
miR-301 17q23.2 Increased MET 
 
1.5.1 MicroRNA 181a 
 
MiR-181a has been shown to be up-regulated in HCC, and is found especially to be up-
regulated in Hepatic Stem Cell-like HCC (HpSC-HCC) [78]. These are HCC cells that are 
EpCAM and AFP positive (i.e. EpCAM
+
AFP
+
 HCC), which respectively, serves as a 
hepatic stem/progenitor cell-specific marker and a marker indicative for HCC [78]. MiR-
181a is also involved in the activated Wnt/β-catenin signalling pathway in HpSC-HCC 
[78]. This pathway has been found to be over-activated in at least 60% of HCC, as the 
levels of β-catenin protein in the nucleus and/or cytoplasm was found to be increased in 
these cases. One group also found that the expression of β-catenin or Tcf4, a co-
transcriptional activator of β-catenin, induces the expression of miR-181s in HuH7 and 
HuH1 cells.  An activated Wnt/β-catenin pathway often leads to the transcription of genes 
that are involved in cell growth, differentiation and survival [79]. An example of a 
validated mRNA target of miR-181a is RalA [80], which is a protein often dysregulated in 
cancer.  These findings may indicate the significant involvement of miR-181a in liver 
cancer. In this study, we propose to investigate the overall effect of miR-181a in HepG2 
cells, especially on important cellular aspects like cell growth, cell cycle and changes in 
protein profile. We also delve into the molecular dynamics of miR-181a in HepG2 cells, 
particularly, identifying its potential mRNA targets as well as the various cancer-related 
pathways that it may affect. By performing both an overall and a molecular study of miR-
35 
 
181a, we gain an insightful knowledge of its mechanisms of action and identify it as a 
potential target in liver cancer therapy. The following lists the mature sequence of miR-
181a; its seed region in bold. 
5’ AACAUUCAACGCUGUCGGUGAGU 3’ 
1.6 Protein Profiling Using Liquid Chromatography Mass Spectrometry 
 
Proteomics is the study of the complete set of proteins expressed by the genome of a cell. 
This includes proteins with post transcriptional modifications, phosphorylation and 
glycosylation. As proteins are the ‘nano-machines’ of cells, their expression levels, 
functions and interaction network determine the state of the cell. It is more significant to 
study the changes in protein levels as compared to gene levels. Proteins are therefore, 
usually the target of drugs during drug-related therapies. The study of proteins first 
requires them to be resolved. Two platforms are often used: 1) Gel-based proteomics; 2) 
Chromatography-based proteomics. In gel-based proteomics, 2-D gel electrophoresis 
coupled to mass spectrometry (MS) is commonly employed. In this method, proteins are 
separated based on two dimensions. The first dimension separates proteins along a pH 
gradient while the second dimension further separates the proteins according to their 
molecular weight (SDS PAGE). By staining the proteins and comparing the protein 
patterns between gels of different samples, unique proteins may be identified. The protein 
spots of interest may be subsequently in-gel enzymatically digested with trypsin and sent 
for MS peptide sequence analysis. One disadvantage of this method is that proteins that 
are low in abundance may be missed during gel-staining.  
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On the other hand, chromatography-based staining circumvents the need for gel-staining 
and peptide extraction. It also ensures detection of low abundant proteins because the 
entire sample may be sent for MS screening with pre-purifying using liquid 
chromatography (LC). Hence, chromatography-based proteomics have since replaced the 
use of 2-D gel electrophoresis MS. Particularly, high performance liquid chromatography 
(HPLC) and capillary electrophoresis, a liquid-based technique, is a feasible approach 
used to identify low abundance and low resolution proteins. This method is able to 
effectively resolve the high degree of complexity of the cellular proteome and detect low 
abundance-proteins. Therefore, it is the method of choice in our study of cellular protein 
profiles. In this section, we will describe the theory and procedure of the liquid 
chromatography-mass spectrometry (LC-MS) technology for our protein profile analysis.  
The coupling of gas chromatography to mass spectrometry (GC-MS) eventually led to the 
advent of the LC-MS. The LC-MS is more complicated than the GC-MS, due to the 
incompatibility of continuous liquid streams to the different MS ion sources. However, a 
vast development in MS has been achieved throughout the years, and by mid 1990s, the 
LC-MS was finally introduced into clinical biochemistry laboratories for functional 
studies. The main advantages of coupling LC to MS over the conventional detectors are 
its high specificity and ability to handle complex mixtures.  A schematic diagram of an 
LC-MS equipment is shown in Figure 4. 
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Figure 4. Schematic diagram of an LC-MS equipment. Samples enter the HPLC via the autosampler, gets pumped 
and separated through columns and finally detected by MS. 
1.6.1 Liquid Chromatography 
 
In this technique, the sample is first resolved by LC. There are many types of columns 
available for this purpose, each separating the samples according to different properties. 
Table 3 shows a list of common types of columns currently available. 
Table 3. Specifically designed columns and their separating principles. 
Type of Column Separation Mode 
Normal-Phase Columns               Polarity. Polar bound phase with nonpolar mobile phase 
Reverse-Phase Columns Polarity. Nonpolar bound phase with a polar mobile phase 
Ion-Exchange Columns               Net charge. Retained ionized material eluted by different 
salt and salt gradients 
Size-Separation Columns              Size (ie. Stokes radius). 
Other Bonded-Phase Silica 
Columns    
Structure (eg. Enantiomeric separation). 
 
In particular, we shall explore the ion-exchange and reverse-phase columns a little further. 
In ion-exchange chromatography, the stationary phase surface displays ionic functional 
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groups that interact with analyte ions of opposite charge. Ions of similar charge get eluted 
while oppositely charged ions are retained on the stationary phase of the column and later 
eluted by increasing the concentration of a similarly charged species that will displace the 
analyte ions from the stationary phase. This is an excellent way of separating proteins 
because proteins have many charged functional groups. By varying the pH and ionic 
concentration of the mobile phase, especially the pH, the proteins will be eluted out of the 
column as its net charge changes from one sign to another. 
In reverse-phase chromatography, a hydrophobic stationary phase and a polar mobile 
phase of column is used. As a result, hydrophobic molecules in the polar mobile phase 
adsorb onto the hydrophobic stationary phase, and hydrophilic molecules in the mobile 
phase will pass through the column and get eluted first. Mixtures of water or aqueous 
buffers and organic solvents are used to elute the analytes from the reversed-phase 
column. The solvents must be miscible with water, and the most common organic solvents 
used are acetonitrile, methanol, and tetrahydrofuran (THF). Other solvents can include 
ethanol or 2-propanol (isopropyl alcohol). Elution may be performed isocratically or by 
using a solution gradient. 
Two reasons why LC is encouraged prior to MS are because firstly, MS alone is unable to 
distinguish isomers due to their same mass. Many biological chemicals exist as isomers, 
with the same molecular mass but different structures. Hence, an additional step of LC 
would aid in differentiating between two isomers. Secondly, LC may be able to help avoid 
or at least alleviate ion suppression, a situation where molecules that are low in abundance 
or poorly ionised are undetected by MS due to the presence of other highly expressed 
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compounds. Pre-purification of the ionisation mixture can separate these components 
from each other so that the masking effects are minimized.  
1.6.2 Mass Spectrometry 
 
After separating the sample within the LC columns, the samples are next prepared for 
detection and identification in the MS. While the LC separates the components, it does not 
identify a compound. Therefore, MS coupled to LC performs this task of identifying the 
compounds present after some pre-purification. Mass spectrometers convert analyte 
molecules into an ionised state, and subsequently analyse them (and any fragment ions 
produced in the ionization process) based on the mass to charge ratio (m/z). One common 
method used to form ions from the analytes is electrospray ionisation (ESI).  This method 
works well with moderately polar molecules and therefore is suitable in the study of 
peptides, metabolites and xenobiotics. Little fragmentation occurs under normal 
circumstances. The liquid sample is pumped and charged through a metal capillary, 
forming a fine spray of charged droplets. Heat and dry nitrogen dries the droplets by 
evaporating the liquid, and any electrical charge is transferred onto the analytes. The 
ionised analytes are next charged through a vacuum, through a series of small apertures 
and focusing voltages, and finally detected. Small molecules with a single charge-carrying 
functional group tend to carry a single charge while larger molecules with multiple 
charge-carrying functional groups (ie. Peptides and proteins) can carry multiple charges. 
This difference in ion charges within a sample can be used to determine analytes up to 
100kDa. This is the basic working principle of ESI in MS. Many variations of ESI have 
been developed to improve on the quality of detection.  
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While ESI is useful for ionising biological molecules, neutral and low polarity molecules 
may not be efficiently ionised by this method. Instead, atmospheric pressure chemical 
ionisation (APCI) may be a better option. In this method, gas and solvent that have been 
ionised in the ion source react with the analyte and transfers their charge to it. 
Alternatively, atmospheric pressure photo-ionisation (APPI) uses photons to excite and 
ionise molecules. These options are useful for small, thermally stable molecules not easily 
ionised by ESI. 
Following ionisation, the ions are accelerated through a mass analyser. The quadrupole 
analyser is the component in a MS responsible for filtering sample ions based on their m/z 
value. This is achieved by using a combination of constant and varying voltages, resulting 
in a mass spectrum. Stepping voltages may be used to focus the detection a range of ions 
of a certain m/z value. While the ionisation process itself produces little or no 
fragmentation, ions may be made to fragment by passing them through a collision cell. In 
the collision cell, the ions collide with an inert gas such as nitrogen or argon. A collision 
cell may be placed between two mass analysers, also known as a triple quadrupole mass 
spectrometer. One main benefit of using a tandem MS is the increased specificity in its 
detection. The product ion scans contain both structural information about the analyte and 
confirms its identity with greater certainty [81]. Tandem MS is frequently used in LC-MS 
applications.  
Another popular mode of analyser is the time-of-flight (TOF). Ions are accelerated 
through a high voltage and reach the detector at different times, depending on their m/z 
value. Ion trap analysers introduce an inert gas into the trap and ions are fragmented 
several times before the final mass spectrum is obtained. Hybrid analysers combine the 
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different analysers in the MS. When the third quadrupole of a triple quadrupole MS is 
replaced by a TOF analyser, a hybrid MS (QTOF) is produced. QTOF is widely used in 
proteomics. If an ion trap analyser is replaced for the third quadrupole, a QTrap MS is 
formed.  
In our study, we employ a QTOF MS.  It has a high sensitivity, high resolution and mass 
accuracy. Q1 in a QTOF MS is operated in the mass filter mode to transmit only the 
parent ion of interest. These ions are accelerated before they enter the collision cell Q2, 
where they get fragmented due to collision with inert gas molecules. If no collision is 
desired, a single mass spectrum can be obtained by setting the collision energy to below 
10eV. The fragmented ions are cooled, re-focused and re-accelerated into the ion 
modulator of the TOF analyser. A pulsed electric field applied across the modulator gap 
changes the direction of the ions to a path perpendicular to that of its original direction, 
where they accelerate in the accelerating column and mass separation occurs. Ions reach 
the ion mirror and get deflected to the TOF detector where the mass spectra are recorded 
[82]. Figure 5 shows the trajectory of ions in a typical QTOF MS. 
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Figure 5. Schematic diagram of a tandem QTOF MS [82]. Ions are accelerated and collided with inert gas molecules 
to form daughter ions in Q1 and Q2 of the QTOF. The fragmented ions are re-accelerated in the ion-modulator and a 
subsequent electric pulse applied such that it changes the direction of the ions perpendicularly, where they then 
accelerate and separate. They are finally deflected into the TOF detector where mass spectra are recorded. (Permission 
from ref.81 was obtained from publisher to use this figure). 
 
1.6.3 LC/MS Software 
 
Data analysis software is employed to extract and interpret information from MS datasets. 
Molecules detected by MS are next identified through a MS database search. At present, 
the standard libraries of mass spectral data that are commonly used include Swiss-prot, 
NIST and Wiley et al. Current limitations of the LC-MS technique lie primarily in the 
separation speed, peak resolution, data analysis and cost.  
1.6.4 Applications of LC-MS/MS 
 
The LC-MS/MS technology may be used in a variety of applications. Millington et al. 
utilised this technology in the screening of neonatal dried blood spots for errors of 
metabolism. Dried blood spots are extracted and derivatised and scanned for a number of 
marker amino acids and acyl carnitines. This may also be applied to screening other 
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conditions, such as sickle cell anaemia, galactosaemia, lysosomal disorders, disorders of 
porphyrin, purine and pyrimidine, peroxisomal and bile acid metabolism. Also, instead of 
measuring the levels of metabolites, the amounts of enzymes may be measured instead.  
Apart from the biochemical screening for genetic disorders, LC-MS may also be applied 
in therapeutic drug monitoring and toxicology. The study of drug therapy and their 
variable cross-reactivity with metabolites have been improved with the tandem use of the 
LC-MS. LC-MS can be used not only to confirm the structure of the final metabolite 
product and its impurities, but also to study the precursor purity, intermediate compounds 
in the synthesis pathway, and the completeness of the drug conversion.  It has been used 
to assay multiple drugs at the same time, due to the capacity to multiplex LC-MS assays, 
making it a more convenient assay as compared to immunoassays.  
Many other types of studies may be performed with the LC-MS. Vitamins, steroid 
hormones and proteins are a few of them that may be studied. Some studies use LC-MS 
for the analysis of specific proteins from complex biological samples. Chang group 
developed a LC–MS/MS method for the quantitation of a large peptide, T-20 and its 
metabolite in human plasma. The method was developed and used for analysing 
pharmacokinetic profiles and metabolite of samples treated by the HIV fusion inhibitor 
peptide drug [83]. Lin described a LC–MS/MS method for the determination of levovirin 
in rat and Cynomolgus monkey plasma, and the assay was validated and used in 
pharmacokinetic studies in rats and monkeys [84]. Feng et al. [85] has shown the 
feasibility of using this method of protein profiling by applying the iTRAQ-coupled 2-D 
LC-MS/MS analysis to reveal and quantify the differences of protein expression levels of 
normal HepG2 cells and those transfected with HBx of three different genotypes (A, B 
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and C). Their results showed that HBx alters the expression levels of proteins involved in 
metabolic enzymes, signalling pathway and cytoskeleton regulation. Proteins regulating 
cell migration were also successfully identified via this comparative proteomics approach. 
The same group did another study [86] using this approach in the identification of 
secreted proteins in their cell-based HBV replication system to establish potential 
biomarkers of liver disease development. Zhang et al. [87] identified enzymes associated 
with angiogenesis in HBV replicating RPHs and HepG2 cells by 2-D LC-MS/MS analysis. 
The identified proteins may lead to a novel anti-angiogenic HCC therapy based on tumour 
vascular targeting. 
These studies highlight the significance of the LC-MS/MS approach in protein profiling, 
as it is able to identifying novel markers indicative of diseases as well as explain the 
mechanisms involved in disease development. In this project, a similar method of 
proteomics analysis will be applied in the identification of differentially expressed 
proteins upon the transfection of miR-181a in HepG2 cells. Their functions and effects 
will then be explored.  
1.6.5 Quantitative Proteomics  
 
As mentioned earlier, the coupling of LC to MS enables the detection and identification of 
unknown compounds like drugs, proteins, etc. Proteomics refers to the entire complement 
of proteins expressed in a given cell, tissue or organism. In our study, we are interested in 
the proteomics of HepG2 cells transfected with miR-181a. While it is useful to identify 
the proteins present in the samples, a quantitative proteomics approach is able to yield the 
difference in protein levels of different samples. MS itself is not inherently quantitative; 
inaccuracies may occur due to the differences in ionisation efficiencies, and the peaks 
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obtained in a mass spectrum is not a good indicator of the amount of analyte in a sample. 
Relative quantitation is still possible using MS alone, but may be less sensitive to 
experimental bias. Moreover, only one sample may be analysed in a single run, making it 
a relatively inconvenient method to study larger sample sizes.  
One way to circumvent these problems would be to incorporate stable isotope labels, such 
as isotopic tags, to the samples. What this does is to cause a mass shift of a labelled 
protein or peptide in the mass spectrum.  Differentially labelled samples are combined and 
analysed together, and the differences in the peak intensities of the isotope pairs 
accurately reflect the difference in the abundance of their corresponding proteins. Known 
concentrations of labels may be added to samples for absolute quantification of target 
proteins. Many types of labels are available, including isotope-coded affinity tags (ICAT), 
tandem mass tags (TMT), isobaric tags for relative and absolute quantitation (iTRAQ), 
metal-coded tags, and stable isotope labelling with amino acids in cell culture (SILAC). 
Table 4 shows the principles of these labelling methods. 
Table 4. Principles of ICAT, iTRAQ, metal-coded tags and SILAC. 
Labelling 
Method 
Principle 
ICAT Two-sample simultaneous quantitation. One sample is labelled with light 
hydrogen while the other, with a heavier version (ie. Deuterium).  
iTRAQ Up to eight samples may be studied simultaneously. Samples are labelled 
with reagents as in Figure 6. 
Metal-
coded tags 
A macrocyclic metal chelate complex loaded with different lanthanides 
(metal (III) ions) forms the essential part of the tag.  
SILAC Two-sample simultaneous quantitation. Labelling occurs at cell culture 
level. Cells of one sample is fed with growth medium containing normal 
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amino acids while cells of the other sample is fed with growth medium 
containing amino acids labelled with stable (non-radioactive) heavy 
isotopes.  
 
There are three major types of labelling: 1) Metabolic labelling; 2) Protein labelling; 3) 
Peptide labelling. Peptide labelling has the advantage over protein labelling by increasing 
the specificity and accuracy of proteins identified.  
Of all the developed stable isotope-based quantification methods, iTRAQ has gained 
much popularity as it allows up to eight samples to be examined within one experiment. 
The reagents are composed of an amino reactive NHS group coupled to a balancer and 
reporter group. Using iTRAQ 4-plex to illustrate, up to four samples can be done in a 
single experiment, with four different reporter groups (MW: 114Da, 115Da, 116Da, 
117Da). Accordingly, the molecular weights of the balancers are: 31Da, 30Da, 29Da, 
28Da. Each reporter group is linked to a balancer, contributing to a total molecular weight 
of 145. The NHS group labels all peptides at the 22 lysine side chain. At the first MS, the 
same peptides (from different samples) will elute at the same retention time as they have 
the same molecular weight. At the second MS (MS/MS), the balancer is lost and the label 
dissociates and releases the reporter group as a single charged ion of masses 114Da, 
115Da, 116Da, or 117Da, respectively. The relative peak areas of the reporter groups 
indicate the contribution of each sample to the total peptide present, providing a measure of 
relative abundance. The principle of iTRAQ labelling is shown in Figures 6 and 7. Briefly, 
sample proteins are extracted and digested into their peptides and labelled with iTRAQ 
reagents. Different samples are labelled with different iTRAQ reagents, each with a 
different reporter group. The underlying principle is that, the mass difference resulting 
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from the introduction of the individual stable isotope provides a ratio for the reporters, and 
this is directly corresponds to the ratio of the analytes. The samples are then pooled and 
separated sequentially on the multi-dimensional columns of the LC based on charge or 
hydrophobicity of the ionized analytes and eluted into the MS for identification and 
quantification. On-line libraries of information and sequence structures of polypeptides 
are available to aid in quickly identifying the peptide sequence, and a bottom-up approach 
is taken to identify the original protein. Generally, two or more unique peptides are 
usually sufficient to recognize a protein.  In our study, an iTRAQ LC-MS/MS was applied 
in studying the biological effects of miR-181a in HepG2 cells.  
 
 
Figure 6. iTRAQ reagents and their chemical structures. Up to 8 samples may be labelled per experiment (Applied 
Biosystems). The labelling reagent consists of a quantification (reporter) group (N-methylpiperazine), a balance group 
(carbonyl), and a hydroxyl succinimide ester group that reacts with the N-terminal amino groups of peptides and the 
amino groups of lysine. (Adapted from http://www.creative-proteomics.com/iTRAQ.htm) 
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Figure 7. Summary of iTRAQ-based LC-MS. Proteins from each sample are denatured, reduced and digested into 
peptides, and labelled with an iTRAQ reagent. Samples are pooled and sent for LC-MS analysis, where the peptides are 
identified and quantified simultaneously. The signal intensity ratios of the reporter groups indicate the ratios of the 
peptide quantities. The MS/MS spectra of the individual peptides show signals reflecting amino acid sequences and also 
show reporter ions reflecting the protein contents of the samples. A database search is performed using fragmentation 
data to identify the labelled peptides and hence the corresponding proteins whilst the iTRAQ mass reporter ion 
relatively quantifies the peptides. (Adapted from http://www.creative-proteomics.com/iTRAQ.htm) 
 
A mass spectrum consists of both fragmentation and quantitation data of the peptides 
detected. As the peptides enter the MS, they are ionised and fragmented in the collision 
cell into daughter ions, which are subsequently accelerated through the TOF and 
detected. There are several bonds that may be broken during fragmentation. The spine 
of a peptide consists of three bonds: C-C, C-N and N-C. Breaking any of these bonds 
would result in daughter ions that may be known as A, B, C X, Y or Z ions. Figure 8 
shows the possible ions formed when any of these bonds are broken. The most 
common types of ions formed are the B and Y ions.  
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Figure 8. Possible daughter ions after peptide fragmentation. Depending on which bonds are broken during collision 
in the MS, ions A, B, C, X, Y or Z may be formed. Their masses are detected and correspond to the molecular mass of 
the ions (http://www.weddslist.com/ms/tandem.html). (Permission from owner of website was obtained to use this 
figure). 
Based on the mass detected by the MS, the daughter ions and their structures may be 
inferred. A bottom-up approach is used to piece the original peptide back together and 
it can then be identified and quantified. The corresponding protein may be 
subsequently identified and quantified, and protein expression in different samples 
compared. 
2. Aims and Objectives 
2.1 Global study of miR-181a in HepG2 cells 
The first aim of this project is to investigate the overall effects of miR-181a in HepG2 
cells. We will employ the use of the LC-MS/MS to obtain a protein profile of the cells 
transfected with either a control miRNA, miR-181a or its inhibitor. The differential 
expression of proteins obtained that are both significant and pivotal in cancers would 
give us a preliminary outlook on what “class” of miRNAs miR-181a may belong to (ie. 
An oncogene or a tumour suppressor). Following protein profiling, we next assess how 
miR-181a affects critical cancer-related processes. We will focus on cell proliferation 
and cell cycle as these are important processes often found altered in cancers.  
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2.2 Molecular Study of miR-181a in HepG2 cells 
 
With the results obtained from the studies performed above, we will then delve into the 
molecular level and identify the direct mRNA targets of miR-181a in HepG2 cells, both in 
vitro and in the cellular environment. This may be able to explain some of the observed 
phenotypes in earlier experiments. Apart from direct targets, because of the non-specific 
nature of miRNAs and the interconnectedness of the protein network in cells, we would 
also expect other downstream effects of the introduction of a single miRNA in cells. 
Therefore, we propose to also study the effect of important cancer-related pathways and 
their transcription factors when miR-181a is transfected into HepG2 cells. We will also 
carry out a PCR array analysis to try to identify more targets of miR-181a, taking in mind 
that the action of miRNAs is usually found at the translational level. All these, when taken 
together, would hopefully be able to elucidate the general function of miR-181a in HepG2 
cells. 
3. Materials and Methods 
 
2.1 Cell Culture  
HepG2 (Human hepatoma cell line) cells were obtained from American Type Culture 
Collection (ATCC), maintained and passaged in  Minimal Essential Medium (MEM) 
(Gibco, Invitrogen), supplemented with 10% fetal bovine serum (FBS) (Gibco, 
Invitrogen), 1% anti-mycotic (penicillin, streptomycin, and amphotericin) (Invitrogen) at 
37°C in a 5% CO2 incubator. Cells were passaged every 2–3 days at 80–90% confluency.  
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Subculturing of cells was carried out using 0.25% trypsin-EDTA (Gibco, Invitrogen). 
Briefly, at confluence, complete growth media was aspirated and the adherent cell 
monolayer gently washed with warm sterile phosphate-buffered saline (PBS, 8 g/L NaCL, 
1.44 g/L Na2HPO4, 0.24 g/L KH2PO4, pH 7.4) (Lonza). PBS was next aspirated and 1ml 
of 0.25% trypsin-EDTA added to the cell monolayer grown in 100mm petri dishes 
(Greiner Bio-One). Cells were incubated in a 37
o
C, 5% CO2 incubator until most of the 
cells became detached. 4ml complete media was added to neutralize the trypsin, cells 
collected in a tube and centrifuged for 4 min at 1000 rpm at room temperature using a 
bench-top centrifuge (Sigma Aldrich). The cell pellet was then resuspended in complete 
growth media and divided into individual tissue culture wares. 
For cryopreservation of cells, cells were trypsinized and pelleted as above. Resuspended 
cells were aliquoted into 2ml plastic cryogenic vials (IWAKI) and tissue culture grade 
dimethylsulphoxide (DMSO) (Sigma Aldrich) was added to a final concentration of 10%. 
The cryovials were put into the 4
o
C fridge for 30min, then -20
o
C freezer for 4h, overnight 
at -80
o
C and finally transferred and stored in liquid nitrogen the following day. 
2.2 Determination of Cell Number 
 
Manual Counting 
Cells were manually counted using a Neubauer haemocytometer (Baxter Scientific). After 
trypsinization and neutralization, the cells were appropriately diluted down and 10μl of 
cell suspension loaded into one chamber of the haemocytometer. Excess liquid was 
blotted off and the cells were allowed to settle on the slide for 30s. The number of cells in 
each of the four corner and central squares was counted under an inverted microscope 
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(Olympus) under a 10X magnification using a hand-held counter. The number of cells per 
millimetre and total cell number were determined using the following calculation: 
ntedsquarescou
ctordilutionfaXXedcellscount
mlCells
#
..10..#
/
4
  
volumesuspensionXmlCellscellTotal ../#   
2.3 Cell Transfection 
Transfection of cells was carried out via different techniques, depending on the 
subsequent analysis carried out. Most of the transfections were carried out using 
electroporation, as this method has shown to be of high efficiency. In this method, cells 
were transfected in Cell Line Nucleofector Solution V (Lonza). 24h prior to transfection, 
2.5 × 10
6
 cells were seeded in 100mm tissue culture dishes. Upon adherence and 
confluence, the cells were serum starved with 2% FBS MEM for 16-24h before being 
transfected with various concentrations of synthesized miRNAs (Dharmacon). We chose 
to perform a starvation step for this length of time because it has been shown by other 
studies that the longer the starvation period (up to 72h), the larger the proportion of cells 
in the G0/G1 stage, therefore successfully synchronizing the cells according to the 
baseline level of the cell cycle [88]. This is important in our study because we are 
interested in cell cycle analysis and minimal interference would be preferred.  Many other 
studies have also used serum starvation as a form of synchronization such that cells are at 
the same ‘starting point’ before the actual experiment is conducted [89]. However, we 
note that despite the advantage of this, serum starvation itself may pose as a form of stress 
for the cells, indirectly causing unwanted cellular reaction like apoptosis. Therefore, a 
final starvation duration of 16h was chosen for our studies. Briefly, HepG2 cells were 
53 
 
resuspended in 100μl Nucleofector Solution V. miRNAs were added and transferred into 
the specialized cuvettes provided. Electroporation was carried out using Program T-28 
(HepG2 high efficiency). 500μl warm complete growth media was added to the 
transfected mix and carefully transferred, using the plastic pipettes provided, into 100mm 
tissue culture dishes containing 10ml complete growth media. The transfected cells were 
allowed to grow at 37°C, in a 5% CO2 incubator for an appropriate amount of time before 
harvesting or continuing with subsequent assays. 
2.4 miRNA Quantification  
 
To ensure successful transfection of miR-181a in the cells, a real-time reverse 
transcription polymerase chain reaction (RT-PCR) was carried out to quantify the amount 
of miR-181a in the cells. The miScript PCR system (Qiagen) was used for the precise 
real-time quantification of miR-181a. Specifically, the miRNeasy mini kit (Qiagen), 
miScript PCR starter kit (Qiagen) and the miScript primer assay (Qiagen) were used 
according to the manufacturer’s instructions for this purpose. 
2.4.1 Total RNA Extraction 
 
Total RNA was extracted using the miRNeasy mini kit. Cells were harvested, pelleted and 
disrupted by vortexing in 700μl QIAzol lysis reagent for 1min. The homogenate was left 
on the bench-top for 5min at room temperature. 140μl chloroform was added to the 
homogenate, vortexed for 15s and left on the bench-top for 3min at room temperature. 
The mixture was centrifuged at 4
o
C at 12,000 x g for 15min. The upper aqueous phase 
was collected into a new collection tube (supplied) and 1.5 volumes of 100% ethanol 
added and mixed.700μl of sample was added into an RNeasy Mini spin column in a 2ml 
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collection tube and centrifuged at 14,000rpm for 15s at room temperature. The flow 
through was discarded and the procedure repeated with the remaining sample. 700ul 
Buffer RWT was added to the column and centrifuged at 14,000rpm for 15s and the flow 
through discarded. 500μl Buffer RPE was next loaded onto the column and centrifuged as 
before. Another 500μl Buffer RPE was loaded again and centrifuged for 2min. To elute 
RNA, the column was transferred to a new 1.5ml collection tube and 40μl RNase-free 
water added directly on the membrane. The tube was centrifuged at 14,000rpm for 1min 
and repeated again with another 40μl RNase-free water to obtain a total RNA elution 
volume of 80μl. The RNA was quantified using a nanodrop spectrophotometer.  
2.4.2 Reverse Transcription of Total RNA 
 
 The cDNA was synthesized using the miScript HiFlex buffer instead of the HiSpec buffer 
because a concurrent quantification of mRNA was performed. Each reaction of reverse 
transcription master mix was prepared on ice as follows: 4μl 5X miScript HiFlex Buffer, 
2μl 10X miScript Nucleics Mix, 2μl miScript Reverse Transcriptase Mix, 1μg RNA 
template and a variable amount of RNase-free water to make up a total volume of 20μl. 
The mixture was incubated at 37
o
C for 60min and 95
o
C for 5min and immediately 
proceeded with real-time PCR.  
2.4.3 Real-time PCR 
 
For detection of the mature miRNA, each reaction mix was prepared by adding 12.5μl 2x 
QuantiTect SYBR Green PCR Master Mix, 2.5μl 10x miScript Universal Primer, 2.5μl 
10x miScript Primer Assay and an appropriate amount of cDNA template and RNase-free 
water. The mix was transferred to 0.2ml white strip tubes (Bio-Rad) and sealed with 
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optical flat strip caps (Bio-Rad). The real-time PCR was carried out on the IQ5 Multicolor 
Real-time PCR detection system (Bio-Rad). The cycling program was: 95
o
C for 15min 
(PCR initial activation step); repeat 40 times the following: 94
o
C 15s, 55
o
C 30s, 70
o
C 30s. 
Microsoft Excel formatted data, including the amplification analysis, experimental report, 
melting curve analysis and threshold cycle number (Ct) were automatically provided by 
IQ5 optical system software version 2.0  (Bio-Rad). The fold changes were calculated as 
follows: 
Sample ΔCt=Ct sample-Ct β-actin ;  ΔΔCt= Sample ΔCt-Control ΔCt;  
Fold change (Sample vs Control) = 2
 -ΔΔC
t    
2.5 Protein Profile Preparation and Labeling with iTRAQ Reagents  
 
Cell pellets were lysed in 200μl 8M urea, 4% (W/v) CHAPS and 0.05% SDS (W/v) on ice 
for 20min with regular vortexing. Cell lysate was centrifuged at 12,800rpm for 45min at 
4°C, supernatant collected, and protein quantified using the Bradford Protein Assay 
(Biorad). A standard curve was established using BSA as a control (Further details under 
the Materials and Methods for ‘Western blot Validation of LC-MS/MS Results’). 100μg 
of each sample was protein precipitated by the addition of 4 volumes of cold acetone and 
stored at -20° C for 1h. The samples were centrifuged for 5min at 12,040rpm and 
supernatant removed. Precipitated proteins were dissolved in the dissolution buffer, 
denatured and cysteine-blocked as described in the iTRAQ protocol (Applied Biosystems). 
Each sample was then digested with 20μl of 0.25μg/μl sequence grade modified trypsin 
(Promega) solution at 37°C overnight and labelled with the iTRAQ tags as follows: 
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HepG2 transfected with miR-mimic control: iTRAQ 114; HepG2 transfected with miR-
inhibitor control: iTRAQ 115; HepG2 transfected with miR-181a: iTRAQ 116; HepG2 
transfected with miR-181a inhibitor: iTRAQ 117. Labelled samples were pooled before 
analysis. To verify that sample preparation techniques do not interfere with digestion and 
labeling procedures, BSA standard solution (Pierce) was also enzymatically digested with 
trypsin and labelled with the iTRAQ reagents as previously stated. These differentially 
labelled digests were mixed at a ratio of 1: 2: 1.5: 2 and analysed by LC-MS/MS. 
2.5.1 On-line 2D Nano-LC-MS/MS Analysis 
 
The Agilent 1200 nanoflow LC system (Agilent Technologies) was used along with the 
6530 Q-TOF mass spectrometer (Agilent Technologies) for this purpose [90]. A total of 
3μl of the pooled sample peptide mixture was loaded onto the PolySulfoethyl A strong 
cation exchange column (SCX) (0.32 x 50 mm, 5 µm). The peptides that do not bind to 
the SCX column is subsequently trapped in the ZORBAX 300SB-C18 enrichment column 
(0.3x5mm, 5um) and washed isocratically with loading buffer 1 (5% acetonitrile, 0.1% 
formic acid) at 0.5 ml/min for 100min to remove any excess reagent. Next, the enrichment 
column is switched into the solvent path of the nanopump. Peptides were eluted using 
buffer 2 (0.1% formic acid) and buffer 3 (95% acetonitrile, 0.1% formic acid) with a 
nanoflow gradient increasing from 5%-80% buffer 3 over 100 min at a flow rate of 500 
nl/min for each analysis. An increasing concentration of acetonitrile elutes the 
concentrated sample and further separation is achieved onto the analytical Zorbax 300SB 
C-18 reversed-phase column (75umx50mm, 3.5um). Survey scans were acquired from 
m/z 300-1500 with up to two precursors selected for MS/MS from m/z 100-2000. 
Following the completion of the first analysis, the enrichment column is switched again 
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into the solvent path of the SCX. Increasing concentrations of buffer 4 (KCl salt solution 
from 10mM to 500mM) is used to elute the retained peptides from the SCX column by 
sequential injection, followed by valve switching and reversed phase chromatography, 
respectively.  
2.5.2 Data Analysis and Interpretation 
 
Following the separation of peptides, we proceeded in the identification and quantification 
of proteins detected. The Spectrum Mill MS Proteomics Workbench (Agilent 
Technologies, Software Revision A.03.03.084 SR4) was used to identify proteins and to 
quantify their relative abundance. Each MS/MS spectrum was searched for the species of 
‘Homosapiens’ in the UniProt_sprot_20100123 database. The searches were run using the 
following parameters: fixed modification of methylmethanethiosulfate-labelled cysteine, 
fixed iTRAQ modification of free amine in the amino terminus and lysine. Other 
parameters such as tryptic cleavage specificity, precursor ion mass accuracy, and fragment 
ion mass accuracy were in-built as functions of the Spectrum Mill software. The protein 
profile results were filtered with a protein score greater than 11 and peptide score of at 
least 6, giving a confidence value of more than 99%. Relative quantification of proteins in 
the case of iTRAQ was performed on the MS/MS scans and displayed as the ratio of the 
areas under the peaks at 114 and 115 Da, which were the masses of the tags that 
corresponded to the iTRAQ reagents. The relative amount of a peptide in each sample was 
calculated by the ratio of the peak areas observed at 115.1 m/z over that of 114.1 m/z. 
Sequence coverage was calculated as a result of the number of amino acids observed 
divided by the protein amino acid length. Standard deviation was calculated by analyzing 
protein ratios between the miR-transfected cells and control transfected cells rather than 
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peptide ratios. The following criteria were required to consider a protein for further 
statistical analysis: more than two unique peptides with high confidence (95%) had to be 
identified, and the-fold differences of integral proteins had to be greater than 1.1. 
2.6 Western blot Validation of LC-MS/MS Results 
 
2.6.1 Protein Quantification 
 
The Bradford dye-binding assay was used to measure the total protein concentration in the 
cell lysates. Bovine serum albumin (BSA) (Sigma) (1mg/ml) was used to prepare protein 
standards. 0, 5, 10, 15, 20, 25 and 30μl of BSA were individually pipetted into 1ml 
disposable plastic PLASTIBRAND
® 
cuvettes (Brand). The volume was topped up to 1ml 
with Bradford reagent and mixed by pipetting gently till a homogeneous solution is 
formed. Absorbance at 595nm was measured using a spectrometer. The absorbance values 
were used to plot a BSA standard curve. 
For measurement of sample protein concentration, 10μl of protein sample was diluted in 
990μl of Bradford reagent. 1ml of Bradford reagent without proteins added was used as 
the blank control. The OD was read at 595nm and protein concentration was determined 
against the BSA standard curve. 
2.6.2 Gel Electrophoresis 
 
SDS-PAGE was performed on the Bio-Rad mini-protean electrophoresis system. Each 
1mm thick gel consists of a stacking gel and separating gel. Separating gels were prepared 
by mixing appropriate amounts of 40% acrylamide/bisacrylamide solution (37.5:1, 
acrylamide/bis; Bio-rad) (1.875 ml for 7.5% gel, 3.125 ml for 12.5% gel and 3.75 ml for 
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15% gel) with 2.5 ml of 1.5 M Tris·Cl (pH 8.8), 100μl of 10% SDS, and 100μl of 10% 
fresh ammonium persulfate (APS) (Bio-rad) and H2O to a total volume of 10ml. The 
volumes can be adjusted accordingly. 5μl of N, N, N’, N’-tetramethylethylenediamine 
(TEMED) (Bio-rad) was added just prior to pouring the gel into the gel apparatus setup. 
100μl pure ethanol was immediately placed over the separating gel to rid of bubbles. After 
polymerization, the ethanol was decanted, and a 5% stacking gel was poured on top of the 
separating gel. 4ml of 5% stacking gel was prepared by mixing 0.5ml of 40% 
acrylamide/bisacrylamide solution with 0.5ml 1.0 M Tris·Cl (pH 6.8), 40μl of 10% SDS, 
40μl of 10% APS, 4μl TEMED and H2O. A comb was inserted at the top and the gel 
allowed to polymerize completely before preparing for gel electrophoresis. 
30μg protein per sample was mixed with 1 x loading buffer (62.5 mM Tris·Cl pH6.8, 10% 
glycerol, 2% SDS, 0.05% bromophenol blue), and 100 mM dithiothreitol (DTT) (Sigma) 
and denatured at 90
o
C for 5min. For non-reducing condition, the DTT was omitted. After 
loading the samples into the wells, the gel was run under constant current (20mA) 
condition until satisfactory protein separation was observed. 10μl Novex Sharp Protein 
Standard (Life Technologies) was loaded per lane to verify protein size. 
2.6.3 Gel transfer 
 
The separated proteins were electrophoretically transferred to a Hybond-P Polyvinylidene 
Fluoride (PVDF) membrane (Amersham-Pharmacia) using Mini-PROTEAN 3 
Electrophoresis System (Bio-rad). The polyacrylamide gel obtained after electrophoresis 
was rinsed in water, placed in-between layers of Whatman paper and membrane, cut to 
exact size of the gel, and inserted with 8 layer filter papers soaked in transfer buffer (0.3% 
60 
 
Tris, 1.45% glycine and 20% methanol), with the membrane facing the anode. The 
bubbles were carefully and completely removed by rolling across a glass spreading rod. 
The transfer was performed in 1x transfer buffer at 21V for 50min. The blotted membrane 
was marked and washed with 1x Tris-buffered saline (TBS) (20mM Tris·Cl pH 7.4, 
150mM NaCl) buffer and stored at 4C if not used immediately.   
2.6.4 Immunoprobing 
 
The antibodies used in this study were as follows: (1) 14-3-3σ protein (SC 7681, Santa 
Cruz), (2) α-enolase (SC 100812, Santa Cruz), (3) Hsp-90β (SC1057, Santa Cruz), (4) 
NPM1 (SC 47725, Santa Cruz), (5) p27 (SC 528, Santa Cruz), (6) E2F7 (AB56022, 
Abcam, Biomed Diagnostics), (7) β-actin mouse monoclonal IgG (Sigma A5441). Bands 
were analysed and quantified by ImageJ software. 
The immunoprobing was carried out following the standard protocol. Briefly, the 
membrane was wetted with 1X TBS buffer before being blocked with 5% nonfat milk 
powder in 0.1% TBST (0.1% Tween-20 in 1x TBS) for 1h at room temperature. 
Following blocking, the membrane was incubated with the recommended amount of 
primary antibody in 5% nonfat milk powder in 0.1% TBST overnight at 4°C on a roller. 
After that, it was washed three times with 0.1% TBST for 10min each time. After the 
washings, the membrane was incubated in anti-goat, anti-mouse or anti-rabbit IgG HRP-
conjugated secondary antibody (Thermo) in 5% nonfat milk powder in 0.1% TBST for 1h 
at room temperature on a roller. The membrane was then washed three times as before 
and incubated in the SuperSignal West Pico Substrate solution (Pierce) by mixing equal 
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volumes of the two reagents for 3min and then exposing to Hyperfilm X-ray films 
(Amersham-Pharmacia) for the desired amount of time. 
2.6.5 Stripping and Re-Probing   
 
Where re-probing was done, the membrane was stripped after chemiluminescent detection 
and re-probed with other primary antibodies. Briefly, the membrane was washed in TBST 
for 5min and incubated in sufficient volume of Re-Blot Plus Strong Stripping Solution 
(Merck, Millipore) at room temperature for 15min. The membrane was then blocked and 
re-probed as before.  
2.7 WST-1 Cell Viability Assay 
 
Assessment of HepG2 cell viability was carried out using the WST-1 reduction test. 
Briefly, HepG2 cells electroporated with miRNAs were seeded a 96-well plate and 
incubated for 24h, 48h or 72h. At the end of these time points, 10μl WST-1 solution 
(Roche Applied Science) was added to each well containing 3x10
4
 cells each. The plate 
was incubated at 37ºC for 1h and absorbance measured using a microplate reader 
(Benchmark Plus) at 450nm. 
For HepG2 cells transfected with miRNAs and subsequently treated with cisplatin, the 
transfected cells were seeded in 96-well plates for the various incubation times and then 
treated with 21μg/ml cisplatin for 24h. This concentration of cisplatin was chosen as it is 
found to be slightly less than the LC50 of cisplatin at 24h. This is because we do not wish 
for the cells to fully undergo apoptosis at the point of readout, as a cell viability test 
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requires cells to still be active, albeit weakened by the treatment. Readout was then 
measured as before.  
2.7.1 Cisplatin Concentration Determination  
 
HepG2 cells were seeded in 96-well plates in complete growth media and a range of 
cisplatin concentrations (0-21μg/ml) added to each well. The WST-1 assay was used to 
measure cell viability 24h after cisplatin treatment. LC50 here refers to the lethal 
concentration of a chemical (ie. Cisplatin) such that 50% of the population are killed off 
after a given duration of time. A concentration of cisplatin was chosen as the experimental 
concentration such that the cells are still viable, albeit weakened by cisplatin treatment.  
2.8 Cell Cycle Analysis 
 
Transfected cells were harvested and washed in PBS. They were then fixed in -20
o
C 
methanol (by adding drop wise to the cell pellet while vortexing) for 30min at 4°C. The 
fixed cells were washed twice in PBS and treated with 25μl 20μg/ml Ribonuclease A 
(Biomed Diagnostics). 500μl propidium iodide (Sigma Aldrich) (100μg/ml) was added to 
the cells and left to incubate in the dark at 37
o
C for at least 30min. The cells were then 
analysed by flow cytometry (BD FACSCalibur™). 
2.9 Bioinformatics Study of mRNA Target Prediction 
 
Human miRNA target predictions for miRNA families were obtained from TargetScan 
6.2 (http://www.targetscan.org/) as well as miRanda 
(http://www.microrna.org/microrna/home.do) database. miRò, the miR-ontology database 
was also used as a convenient source of categorizing miRNAs and their targets by 
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diseases, functions or processes that they are involved in. Relevant targets predicted by 
both TargetScan and miRanda were chosen for wet lab experimentation. Putative 
miRNA:mRNA interaction, in TargetScan, was based on the total context score and 
probability of conserved targeting (PCT). The more negative the context score and the 
higher the PCT, the higher the probability of miRNA:mRNA binding.  
Apart from interaction around the seed region, a secondary source of concern, in terms of 
possible miRNA:mRNA binding, would be the extent of RNA folding around the binding 
site. The Mfold web server is an online software that calculates free energies of folding 
(ΔGFold). The more negative the ΔGFold, the higher the probability of RNA folding.  
2.10 Surface Plasmon Resonance (SPR) assay.  
 
Surface plasmon resonance (SPR) is a real-time platform for detecting the binding of 
specific molecules to a partner. Protein interactions, small molecules, nucleic acids, cells 
and viruses and carbohydrates are some of the compounds that can be studied with SPR 
[91]. It typically takes place on the sensor surface of a chip, and its working principle is 
based on the change in refractive index of the interface when the surface condition 
changes. When positive binding occurs, the sensorgram registers a change in angle due to 
the increase in mass bound at the surface. A real-time profile of binding followed by 
subsequent dissociation can be generated, and the kinetics of the binding characterised.  
This provides a quick yet precise method of screening potential mRNA targets of miR-
181a. An illustration of the working platform is shown in Figure 9. 
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Figure 9. Working principles of SPR [92]. As polarized light hits the sensor-gold/buffer interface, it undergoes total 
internal reflection and the reflected light is eventually detected. At the same time, when the light hits the glass, the 
electrons from the gold layer absorbs the energy from the evanescent waves, generating plasmons, reducing the reflected 
light and hence causing a drop in the intensity of light detected. This happens at a certain angle, depending on the angle 
of incidence light. When binding occurs, the increase in mass bound to the interface causes a change in refractive index 
of the solution, thereby altering the angle of reflected light detected. (Permission from ref.89 was obtained from 
publisher to use this figure). 
 
All SPR experiments were run with HBS-EP buffer (10mM HEPES, 150mM NaCl, 
3.4mM EDTA and 0.005% P20 at pH 7.4) on a Biacore 3000 (BIAcore AB, GE 
Healthcare) with a carboxymethylated dextran coated sensor chip (CM5) at 25°C. Two 
surfaces were activated for 7min with 1:1 mixture of 0.2 M N-ethyl-N’-[3-
(diethylamino)propyl]carbodiimide (EDC) and 50mM N-hydroxysuccinimide (NHS), 
before immobilization of 1500 RU of Neutravidin (Pierce, USA) in 10mM sodium acetate 
at pH 6.0 at the flow rate of 10μl/min by standard amine coupling procedure. The surfaces 
were then blocked with 0.5M ethanolamine-HCl at pH 8.5 for 7min. Biotin-labelled 
single-stranded RNA harboring 31bp 3’UTR of CDKN1β mRNA  (5’- 
GGGAGUUUUGAAUGUUAAGAAUUGACCAUCUGC -3’) and 34bp 3’UTR of E2F7 
mRNA (5’- GGGUAUGACGACUUGAAUGUUUAUACUUUUAUUC -3’) were 
captured on sensor chip surface to 200 RU and 430 RU, respectively. Another two empty 
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channels serve as reference. A 2-fold serial injection of miR-181a (180nM, 359nM, 
719nM, 1.44uM, 2.88uM, 5.75uM, 11.5uM, and 23uM) was injected at 10μl/min across 
all the surfaces for 2min, and was then allowed to dissociate for 15min. All the 
sensorgrams were corrected by subtraction of the responses of analytes on the empty 
channel and buffer blanks [93]. Processed data were globally analysed and fit into 1:1 
interaction model to yield the affinity. 
2.11 Transformation 
 
Mammalian expression vectors (Firefly/renilla duo-reporter vector system) with the 3’ 
UTR of CDKN1β and E2F7 cloned downstream of the secreted firefly luciferase reporter 
gene were obtained from GeneCopoeia. These have been sequenced and quality checked 
before subsequent usage. 1μl of DNA plasmid was mixed with 50μl competent cell Ecoli 
strain TOP10 in a microcentrifuge tube. The tube was stored on ice for 10min. It was next 
heat shocked at 42
0
C for 90s and returned to ice immediately for 2min. 450μl fresh LB 
was added and the cells incubated at 37
0
C in a shaking incubator at 250rpm for 1h. 
LB/kanamycin agar plate (1% Tryptone, 0.5% yeast extract, 171mM NaCl, 1.5% agar, PH 
7.0) was prepared and 100μl of transformed bacterial cells was spread on top and 
incubated at 37
0
C overnight in an inverted position. 
2.12 Mini-prep Purification of Plasmids 
 
A single colony of TOP10 was incubated in 5ml sterile LB medium with 100ng/ml 
Kanamycin in a 15ml falcon tube at 37℃ with agitation at 250rpm overnight. The bacteria 
were harvested directly by centrifuging at 2500 rpm for 15min (Beckman Allegra 64R). 
Plasmid extractions were carried out using QIAprep Miniprep plasmid kit (Qiagen). 250μl 
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buffer P1 was used to resuspend the bacterial pellet and transferred to a microcentrifuge 
tube. 250μl buffer P2 was added and mixed gently. 350μl buffer N3 was added, mixed 
and centrifuged at 13,000rpm for 10min. The supernatant was loaded on QIAprep Spin 
Column, centrifuged at 13,000rpm for 30s, and the flow-through discarded. 750μl buffer 
PE was added to the column and centrifuged at 13,000 rpm for 30s, discarding the flow-
through. The column was centrifuged for an additional minute to remove residual buffer. 
The column was placed on a new microcentrifuge tube and 50μl buffer EB (10mM Tris.Cl, 
pH 8.5) added and incubated for 1min. The DNA plasmid was finally eluted out by 
centrifugation for 1min, quantified by nanodrop spectrophotometer and stored at -20℃ 
until further use. 
2.13 Co-Transfection of Plasmids and miRNAs 
 
The co-transfection of DNA plasmids and miRNAs was carried out via electroporation. 
Briefly, 1x10
6
 of overnight starved HepG2 cells were resuspended in 100μl nucleofection 
solution and co-transfected with 4μg DNA plasmid and either 10nM or 100nM miR-181a. 
An additional control vector was also used such that the sequence cloned downstream of 
the firefly luciferase reporter gene is of a random, non-specific targeting sequence. 100K 
transfected cells were seeded in each well of a 24-well plate and incubated with 500μl 
complete growth media at 37℃ overnight.   
2.14 Luciferase Assay 
 
Luciferase is a class of enzyme that is used in bioluminescence, or light production. Many 
different luciferases are available, but the most common ones are those of the fireflies. 
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Their presence, in addition to a substrate luciferin, causes a chemical reaction to occur 
such that light is produced: 
Luciferin + ATP  Luciferyl adenylate + PPi 
Luciferyl adenylate + O2  Oxyluciferin + AMP + Light 
In our study, we make use of this property of luciferase to test for the binding between 
miR-181a and its predicted mRNA targets. A plasmid coding for the firefly luciferase is 
used, modified with the different 3’UTRs of the mRNAs cloned downstream of the firefly 
luciferase reporter gene. Co-transfection of miR-181a and the plasmid into HepG2 cells 
allow for any binding to occur. If binding exists, the transcription of the reporter firefly 
luciferase gene would be inhibited, thereby leading to a lowered bioluminescence detected. 
Figure 10 shows the plasmid used. The plasmid is a firefly/Renilla Duo-Luciferase 
reporter vector (GeneCopoeia, USA), with the Renilla Luciferase reporter gene acting as 
the control reporter in which firefly luciferase is normalised against. Two different 
variations of the plasmids were used, corresponding to the different 3’UTRs of the 
mRNAs cloned downstream of the firefly luciferase reporter gene. An additional control 
vector (C1) (GeneCopoeia, USA) was used that incorporated a random sequence 
downstream of the firefly luciferase reporter gene.  
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Figure 10. Schematic diagram of the firefly/renilla duo-luciferase reporter vector. The 3’UTRs of CDKN1β and 
E2F7 are cloned downstream of the firefly luciferase reporter gene, while a random sequence is cloned in the case of the 
control vector. Renilla luciferase activity is used as the internal control, and the firefly luciferase activity is normalised 
against that measured of renilla luciferase. 
 
The luciferase assay was carried out using GeneCopoeia Luc-Pair™ miR Luciferase 
Assay kit. 24h after co-transfection of plasmids and miRNAs, growth media was aspirated 
and 300μl Solution 1 was added to each well and incubated at room temperature for 3min. 
80μl of cell lysate was removed and transferred into a new 1.5ml microcentrifuge tube. 
Working Solution I and Working Solution II are prepared as follows. To prepare Working 
Solution I: Solution I and Substrate I are warmed up to room temperature and Substrate I 
diluted in Solution 1 in a ratio 1:40. Similarly, for Working Solution II, Substrate II was 
diluted in a ratio of 1:200 in Solution II. Prior to luciferase activity measurement, the 
GloMax 20/20 Luminometer (Promega) was set to measure luminescence for 2s. 20μl of 
Working Solution I was added to each of the 80μl sample and firefly luminescence 
measured (M1). 100μl of Working Solution II was subsequently added and renilla 
luminescence measured (M2). The firefly luciferase luminescence values obtained were 
normalized by taking M1/M2. The stability of the plasmids was also dutifully noted 
throughout the experiments to ensure that no aberrant measurements occurred, which 
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could imply plasmid instability or incompatibility with the cellular environment. This may 
be observed from the raw luminescence values (ie. M2) of the renilla reporter that was 
used in all three plasmids. Because it serves as a constitutively expressed control, the 
measured luminescence should be similar in all experiments where the same amount of 
plasmids was used. Any deviation from the values obtained within a single batch of 
experiments may indicate error and that measurement would not be used for further 
analysis. One thing to note, is that the transfection of the plasmid into the cells is a 
transient process and we are only investigating the interaction, if any, of the miRNA and 
its putative targets’ mRNA 3’UTRs in the cellular environment. Hence, we would expect 
the plasmids’ measured luminescence to be diluted with time.   
2.15 Cignal Reporter Assay Analysis of Cancer Pathways Affected by miR-
181a 
 
The Cancer 10-pathway Reporter Luciferase Kit (Qiagen) in plate format was used in the 
measurement of ten cancer-related signaling pathways.  Electroporation would not be 
possible with this assay format, therefore liposomal transfection was employed. A reverse 
transfection protocol was used as compared to the traditional forward transfection as this 
method of transfection has been found to be more efficient and reproducible.  
This reporter array consists of ten cancer-related pathways that can be screened 
simultaneously.  The signalling pathways included are Wnt, Notch, p53/DNA damage, 
TGFβ, Cell cycle, NFκB, Myc/Max, Hypoxia, MAPK/ERK and MAPK/JNK. Positive 
and negative controls were also included for quality control purposes. The assay came in a 
96-well cell culture plate format, with each column being distinct from the next, 
distinguishable by the different transcription factor reporters dried down in each well. The 
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sample, negative control and positive control reporter transcription factors are as shown in 
Figure 11.  
 
Figure 11. Illustration of the various reporter constructs used in the array. Mixture of constructs of each of the ten 
reporter assays (left), negative control (middle) and positive control (right).  
Briefly, 2pmol of miRNA was diluted in 25μl of pure Opti-MEM (Life Technologies) 
growth media and added to each well of the plate to resuspend the plasmids. 0.6μl 
Attractene (Qiagen) was diluted in 25μl pure Opti-MEM in a separate microcentrifuge 
tube, incubated at room temperature for 5min and added to each well of the resuspended 
plasmids. The Attractene/plasmids-miRNA complex was allowed to form for 20min at 
room temperature. HepG2 cells growing in complete MEM media with 10% FBS were 
washed in PBS and trypsinized, centrifuged and supernatant discarded. The cell pellet was 
resuspended to 4X10
5
 cells/ml in Opti-MEM containing 5% FBS. After 20min of complex 
formation, 100μl of the prepared cell suspension was added to each well containing the 
constructs-miRNA-Attractene complexes, making up to a final volume of 150μl per well 
of a 96-well plate. The plate was mixed gently with a rocking motion and then incubated 
at 37℃ in a 5% CO2 incubator for 16-24h. After 16-24h of transfection, the media was 
aspirated and changed to 75μl complete growth media (MEM with 10% FBS and 1% 
antimycotics) and further incubated at 37℃ for another 24h. The cells were checked with 
the positive control for GFP fluorescence using a fluorescent microscope. Following 
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successful transfection validation, the luciferase assay was developed by using Dual-
Luciferase Reporter Assay System (Promega).  
2.15.1 Developing Luciferase (Plate) Assay  
 
Briefly, the Dual-Glo Luciferase buffer was added to Dual-Glo Luciferase Substrate to 
make up the Dual-Glo Luciferase Reagent. A calculated amount of Dual-Glo Stop & Glo 
Reagent was prepared by diluting the Dual-Glo Stop & Glo Substrate to the Dual-Glo 
Stop & Glo Buffer in a ratio of 1:100. 75μl Dual-Glo Luciferase Reagent was added to 
each well and firefly luminescence was measured after 10min (M1). 75μl of Dual-Glo 
Stop & Glo Reagent was added to each well and the renilla luminescence measured after 
10min (M2). The ratio of luminescence (M1/M2) of firefly to renilla gives the normalized 
luminescent values per well. Luminescence was measured in a Tecan microplate reader 
with a Magellan Data Analysis Software.    
2.16 Target Array Analysis of Direct mRNA Targets of miR-181a 
2.16.1 RNA Extraction and Quantitation 
RNA isolation was carried out using RNeasy mini kit (Qiagen). Briefly, cell pellets were 
resuspended in 350μl buffer RTL. (10μl β-Mercaptoethanol (β-ME) was added to 1ml 
buffer RTL). A 20-gange needle (0.9mm diameter) fitted to an RNase-free syringe was 
used to homogenize the sample, 1 volume 70% ethanol added and mixed well. Samples 
were transferred to RNeasy mini column placed in a 2ml collection tube, centrifuged at 
13,000 rpm for 30s using a bench top centrifuge (Sorvall). The flow-through was 
discarded and 700μl buffer RW1 was added to column and centrifuged at 13,000rpm for 
30s, discarding the flow-through. 500μl buffer RPE was added to column and centrifuged 
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at 13,000rpm for 30s, discarding the flow-through. Another 500μl buffer RPE was added 
and centrifuged at 13,000rpm for 2min. The column was placed in a new 2ml tube and 
centrifuged at 13,000rpm for 1min. The columns were transferred to a new 1.5ml 
collection tube. 30μl RNase-free water was directly added onto the membrane of column 
and centrifuged at 13,000rpm for 1min. The flow-through containing total RNA was 
quantified with a nanodrop spectrophotometer and stored at -80
o
C until further use.  
2.16.2 Reverse Transcription 
 
Reverse transcription was carried out using the RT
2
 First Strand Kit (Qiagen). 0.5μg total 
RNA was added to the genomic DNA elimination mix, incubated at 42
o
C for 5min and 
placed on ice. The reverse-transcription mix per reaction composed of 4μl 5x Buffer BC3, 
1μl Control P2, 2μl RE3 Reverse Transcriptase Mix and 3μl RNase-free water. 10μl of 
this reverse-transcription mix was added to 10μl of genomic DNA elimination mix, 
pipetted to mix and incubated at 42
o
C for 15min, followed by a 95
o
C incubation for 5min. 
91μl RNase-free water was added per reaction and the mixture either stored at 20oC or 
immediately used for real-time PCR.  
2.16.3 Real Time PCR 
 
The PCR components mix per reaction consisted of 1350μl 2x RT2 SYBR Green 
Mastermix, 102μl cDNA synthesis reaction and 1248μl RNase-free water. 25μl of the mix 
was added to each well of the custom made RT
2
 Profiler PCR Array using an 8-channel 
pipettor. The array was sealed with optical thin-wall 8-caps strips. The platform used to 
carry out real-time PCR was Applied Biosystems 7500, with the following cycling 
conditions: 95
o
C for 10min (1 cycle); 95
o
C for 15s, 60
o
C for 1min (40 cycles). An 
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automated baseline was used and the following calculation was used in the analysis of 
results: Sample ΔCt=Ct Sample-Ct Housekeeping gene; ΔΔCt= Sample ΔCt-Control ΔCt; 
Fold change = 2 –ΔΔCt 
2.17 Statistical Analysis  
 
All data are presented as mean ± SD. The Wilcoxon signed rank test was used for 
comparisons of fold changes in cell viability between HepG2 cells transfected with 
controls and miRNAs. 2-tailed Student’s t-test was used for the other analyses where two 
experimental groups of values are being compared. Statistical significance was accepted 
at p < 0.05. Where the means of three or more groups were being compared for statistical 
difference, ANOVA was used. The value of n refers to the number of independent batch 
experiments performed for analysis. 
3. A Quantitative Proteomics Approach in the Study of MicroRNA 
181a in HepG2 Cells1 
 
3.1 Introduction 
 
Currently, not much of miR-181a is known about its role in HCC progression, apart from 
the fact that it is highly upregulated in HCC and HpSC-HCC, and that it is involved in the 
Wnt/β catenin signalling pathway, a pathway often found upregulated in many cancers. 
To study the effect of miR-181a in HCC, we first chose HepG2 cells as our model to 
represent HCC. It is a cell line commonly used in exemplifying HCC and is known to be a 
                                                          
1
 Reproduced in part with permission from [94] Y. Lin Jane Tan, N. A. Habib, W. Ning Chen, A 
Quantitative Proteomics Approach in the Study of MicroRNA 181a in HepG2 Cells, Current 
Proteomics, 9 (2012) 262-271. Reference copyright [2012]. Yi Lin Jane Tan designed and performed 
the experiments, analysed the data and wrote the paper. 
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good representation of human primary hepatocytes, therefore makes a good platform for 
an in depth study of this miRNA. The study of miR-181a in other established HCC cell 
lines would be the next step in the comparison and/or validation of the results of this study, 
but unfortunately is not going to be covered in this project as we are more interested in the 
potential effects of miR-181a as an initial investigation. The effect of miR-181a may be 
studied in two ways: To cause an upregulation of its expression in HepG2 cells or to 
inhibit its expression and examine the downstream effects of the perturbation. This can be 
done by either transfecting the cells with miR-181a or its inhibitor. As miRNAs are 
known to regulate many cellular processes through the binding of mRNAs, its 
introduction would have a profound effect in the protein profile of the cell. Because 
proteins are known to be the ‘molecular machines’ of cells, it is of great interest to study 
how the presence, or inhibition, of miR-181a would affect a cell’s protein profile.  
To do so, we make use of a modern and developed proteomics technique that is able to 
both identify and quantify the global protein profile of a given sample. The LC-MS/MS is 
a rapidly evolving platform for such a purpose, and in recent years, various methods have 
been used alongside this technology in elucidating the proteins that are present in 
biological samples. Among which, the iTRAQ method is the method of choice for our 
study.  
3.2 Results and Discussion 
 
3.2.1 RT-PCR of miR-181a in HepG2 Cells at 24h and 48h Post-Transfection 
 
Before we begin to establish the protein profile, however, we first have to ensure that the 
HepG2 cells have been successfully transfected with miR-181a. Not only that, but we also 
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need to certify that the (new) levels of miR-181a is sustainable, at least for 48h, within the 
cell, because of the transient nature of its transfection. To do so, we have chosen 
electroporation as our method of transfection of miR-181a into HepG2 cells, because this 
technique has been consistently shown to produce a high transfection efficiency. Figure 
12 shows the highly efficient transfection of GFP into HepG2 cells via electroporation. 
After HepG2 cells were transfected with 100nM miR-181a and its inhibitor respectively, 
its relative amount in the cells were quantified by real-time RT-PCR. Figure 13 shows the 
levels of miR-181a at 24h and 48h post-transfection. A significant increase in levels of 
miR-181a is seen in cells transfected with miR-181a (by at least 3 times) while those that 
were transfected with the inhibitor exhibited much lower levels of the miRNA at both 
time points.  This confirms the successful transfection via electroporation of miR-181a 
into HepG2 cells. The levels of miR-181a dropped slightly at 48h as compared to 24h 
post-transfection, albeit insignificant, but were still relatively high as compared to the 
control samples. This means that the transfection of miR-181a, although transient, but was 
still sustainable after a 48h time point at 100nM transfection concentration. We then 
proceeded to analyse the change in protein profile of HepG2 cells due to its transfection.  
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Figure 12. Phase contrast and fluorescence detection of HepG2 cells transfected with GFP plasmid at 24h post 
transfection. (10X magnification level) HepG2 cells were transfected with 4μg GFP by electroporation and incubated 
in complete growth medium. After a 24h incubation, the cells were viewed under a fluorescent microscope and 
compared with phase contrast microscopy. Most cells are observed producing green fluorescence, indicating the high 
transfection efficiency of this method on HepG2 cells. 
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Figure 13. Real time RT-PCR of miR-181a gene expression levels at 24h and 48h post-transfection. Using a 
Student’s t-test, the successful transfection of 100nM of miR-181a via electroporation caused a significant increase (p 
value= 0.0044 and 0.029 for 24h and 48h respectively) (n=3) in miR-181a levels in HepG2 cells as compared to those 
transfected with its inhibitor. 
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3.2.2 LC-MS/MS Analysis of Differentially Expressed Proteins 
 
To understand the mechanisms and effects miR-181a induces in HepG2 cells, we 
proceeded to establish the protein profile of HepG2 cells transfected with this miRNA. 
HepG2 cells serum starved for 16h [95] were transfected with 100nM miR-181a or its 
inhibitor and harvested after a 24h incubation. This time point was chosen because the 
expression levels of miRNAs previously showed a slight decrease after that, albeit 
insignificant. Two different control miRNAs were used: One mimic control and an 
inhibitor control; each is a random sequence and serves as control for miR-181a and miR-
181a inhibitor respectively.  The transfected cells were lysed and proteins extracted and 
labelled with iTRAQ reagents. Experiments were carried out in triplicates and the MS 
result analysed by Spectrum Mill software using UniProt_sprot_20100123 database to 
identify and quantify the protein expression levels of the different samples. 208, 90 and 
298 proteins were identified and quantified in the three experiments respectively. From 
these sets of data, proteins that were found to be consistently dysregulated due to the 
transfection of the miRNAs were chosen for further study. From this list, we further 
sieved out proteins involved in important cancer processes, for example, those involved in 
cell cycle, cell growth and apoptosis. Table 5 lists the proteins we have identified that are 
of interest.  
11 proteins that were consistently found to be differentially expressed between the 
samples in all three independent experiments are listed and categorized according to their 
cellular functions. These included metabolic enzymes, stress proteins/molecular 
chaperones, binding/signalling proteins and transport proteins. The change in protein 
profile from the LC-MS/MS analysis shows a general upregulation of stress proteins in 
78 
 
HepG2 cells transfected with miR-181a. Inhibiting miR-181a, on the other hand, 
generally led to either a drop or no change in stress protein levels. Stress proteins act like 
molecular chaperones and tend to form a protective layer in the cell, shielding the cell 
from trauma, such that they become more resilient. These initial findings may suggest an 
oncogenetic role of miR-181a in HCC. 
Among the proteins listed, a few garnered interest. Namely, heat shock protein 90β (Hsp-
90β), nucleophosmin (NPM1) and 14-3-3σ protein. These proteins are heavily involved in 
cell survival (Hsp-90β) and cell growth (NPM1 and 14-3-3σ), which are crucial processes 
in the development of HCC. Expression of Hsp-90β was found to be increased in HepG2 
cells transfected with miR-181a but decreased in cells transfected with its inhibitor. 
NPM1 was found to be increased in cells transfected with miR-181a but no significant 
change found in those transfected with the inhibitor. 14-3-3σ protein was found down-
regulated in cells transfected with miR-181a. The roles and functions of these proteins 
will explained in further detail under ‘3.2.3 Western blot Validation of LC-MS/MS 
Identified Proteins’. Their representative peptides’ MS are shown in Figure 14. 
Table 5. List of 11 differentially expressed proteins characterized according to their function. The proteins were 
extracted from cell lysates and 100μg of total protein trypsinised and tagged with iTRAQ reagents 114, 115, 116 and 
117. Peptide sequences were read in the MS and proteins quantified and identified. The ratio of expression of samples 
versus control provides the fold increase or decrease in protein expression. 
Table 5 – Differentially expressed protein profile after miRNA transfections.  
Accession 
Number 
Protein name %AA 
coverage 
miR-181a/ 
control 
Mean±SD 
miR-181a 
inhibitor/ 
Control 
Mean±SD 
Peptide 
Count 
Protein 
Score 
Protein 
function 
P06733 Alpha enolase 40 1.31 ± 0.18 
 
 
0.93 ± 0.17 
 
 
12 195.71 Metabolic 
Enzyme 
 
P14618 Pyruvate kinase 
isozymes 
M1/M2 
33 0.93 ± 0.08 
 
0.97 ± 0.08 
 
 
13 196.07 Metabolic 
Enzyme 
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A5A6N7 L-lactate 
dehydrogenase 
B chain 
16 1.47 ± 0.58 
 
1.09 ± 0.43 
 
 
4 44.22 Metabolic 
Enzyme 
 
P15121 Aldose 
reductase 
18 0.76 ± 0.27 
 
0.96 ± 0.23 
 
 
3 32.72 Metabolic 
Enzyme 
 
P10809 60kDa heat 
shock protein, 
mitochondrial 
49 1.32 ± 0.17 
 
0.77 ± 0.17 
 
 
17 291.66 Molecular 
Chaperone/ 
Stress 
Protein 
P61603 10kDa heat 
shock protein, 
mitochondrial 
23 1.18 ± 0.30 
 
1.02 ± 0.15 
 
2 23.79 Molecular 
Chaperone/ 
Stress 
Protein 
P08238 Heat shock 
protein HSP 90-
β 
28 1.19 ± 0.12 
 
0.87 ± 0.09 
 
14 200.86 Molecular 
Chaperone/ 
Stress 
Protein 
P06748 Nucleophosmin 28 1.37 ± 0.21 
 
1.06 ± 0.53 
 
 
6 93.7 Molecular 
Chaperone/ 
Stress 
Protein 
P26599 Polypyrimidine 
tract-binding 
protein 1 
24 1.84 ± 1.59 
 
0.62 ± 0.12 
 
 
5 74.97 Binding 
protein 
P31947 14-3-3 protein 
sigma 
31 0.72 ± 0.10 
 
1.05 ± 0.37 
 
4 51.99 Binding 
protein 
O00410 Importin-5 5 1.01 ± 0.37 
 
0.67 ± 0.20 
 
3 39.92 Carrier/ 
Transport 
Protein 
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Panel A. Hsp-90β 
 
Panel B. NPM1 
 
Panel C. 14-3-3σ 
 
 
 
Figure 14. A representative MS/MS spectrum showing the peptides. The ion assignment were as follows: HepG2 
transfected with miR-mimic control: iTRAQ 114; HepG2 transfected with miR-inhibitor control: iTRAQ 115; HepG2 
transfected with miR-181a: iTRAQ 116; HepG2 transfected with miR-181a inhibitor: iTRAQ 117. Panels A, B and C 
represent spectrum of peptides identified and quantified that showed a consistent change in protein expression levels of 
Hsp-90β, NPM1 and 14-3-3σ protein respectively.    
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3.2.3 Western blot Validation of LC-MS/MS Identified Proteins  
 
Expression levels of proteins identified from the LC-MS/MS analysis were next assessed 
and validated by a Western blot. Total protein from each sample was extracted from the 
cell lysate and 30μg per sample loaded into each well for gel electrophoresis. We have 
successfully probed for the expression of three proteins- Hsp-90β, NPM1 and 14-3-3σ 
(Figure 15 and 16). These three proteins were chosen for further validation because we 
found them to be pivotal and possess well established roles in cancer progression. Not 
only that, but they have been consistently detected in our LC-MS/MS studies, such that 
their expression levels show a trend when transfected with miR-181a, its inhibitor or both 
of them, albeit insignificant at this point in time. The other proteins listed in Table 5, 
despite also being detected in all three independent runs, do not have as strong a link to 
cancer, their trends are not as clear (high standard deviation) or have conflicting roles in 
cancer, as in the case of Hsp-60 [96]. The trends in expression of these three proteins will 
therefore give us a very preliminary outlook of the potential effect of miR-181a in cancer 
progression, which will then be validated with subsequent experiments. Hsp-90β protein 
expression level is seen to drop when miR-181a was inhibited while NPM1 protein 
expression levels increased when miR-181a was overexpressed.  
Stress proteins include the heat shock proteins (HSPs), glucose-regulated proteins (GRPs) 
and ubiquitin. Stress in cells may include hyperthermia, hyperoxia, hypoxia, and other 
perturbations, which alter protein synthesis [97]. Under these conditions, the cells’ 
protective mechanisms are activated, and HSPs in particular, would be highly produced to 
maintain cell integrity. An increase in expression of HSPs has been found in many cancers, 
leading to a shielded environment, allowing cancer cells to grow indefinitely. One reason 
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why HSPs may be overexpressed in cancer could be due to the physiopathological 
features of the tumour microenvironment (low glucose, pH, and oxygen), which tend 
toward HSP induction [98].  
Among the HSPs, Hsp-90 plays a particularly versatile role in cell regulation, forming 
complexes with a large number of cellular kinases, transcription factors, and other 
molecules. Hsp-90β is a molecular chaperone that protects numerous key nodal proteins in 
cells and is especially involved in contributing to the robustness of cancer cells [99]. It 
plays a central role in many important processes like preventing apoptosis, insensitivity to 
anti-growth signals, sustained angiogenesis, limitless replicative potential, tissue invasion 
and metastasis as well as in the self-sufficiency of growth signals in cancer cells. It is 
therefore unsurprising, that the expression of Hsp-90β is often elevated in cancers. An 
example of a protein protected by Hsp-90β is NPM-ALK (a cause of malignant 
transformation) [99]. The decrease in Hsp-90β expression level in HepG2 cells when 
miR-181a was inhibited may cause a weakening in its inherent defence machinery.  
On the other hand, miR-181a transfection causes an increase in the expression of NPM1 
protein. NPM1 is a phosphoprotein found mainly in the nucleus. It is known to be 
involved in a multitude of cellular processes including the assembly and transport of 
ribosomal proteins, centrosome duplication and also acts as a molecular chaperone. When 
expressed at high levels, it is found to promote tumour growth by the inactivation of the 
p53/ARF pathway [100]. Not only that, but it is also found to interact with c-myc and 
NFκB transcription factors. Many studies link excessive levels of NPM1 to cellular 
transformation and are often found in many human cancers including those of the stomach, 
prostate, colon, bladder, and liver. NPM1 overexpression in tumour cells was also found 
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to lead to an increased proliferation and inhibition of apoptosis [101]. Although the study 
of NPM1 in carcinogenesis is well-documented, its mechanism of action lies largely 
unknown. The increase in NPM1 protein level by miR-181a may suggest the oncogenetic 
effect miR-181a exerts in HCC. 
Lastly, 14-3-3σ was found to be down-regulated by miR-181a in HepG2 cells in the LC-
MS/MS and upregulated when miR-181a was inhibited in the Western blot analyses. The 
14-3-3 family of proteins consists of 7 different isoforms, with different functions in cell 
cycle and cell signaling, among which is 14-3-3σ. 14-3-3σ protein plays a role in cancer 
by participating in the cell cycle [102, 103]. It is known to be a negative regulator of the 
cell cycle by regulating the cyclin-dependent kinases (CDKs) and is found to be lowly or 
not expressed in HCC [104]. It is a p53 inducible gene following DNA damage and in 
turn also regulates the level of p53, thereby forming a positive feedback loop that 
reinforces each other. 14-3-3σ expression was found to lead to a stabilized expression of 
p53 and enhanced p53 transcriptional activity [103]. Additionally, it was found to 
antagonize the biological functions of Mdm2 by blocking Mdm2-mediated p53 
ubiquitination and nuclear export [103]. It has been shown that the overexpression of 14-
3-3σ protein in breast cancer cell lines inhibits cell proliferation and prevents anchorage-
independent growth [105]. This suggests that 14-3-3σ may have a tumour suppressive role, 
and its increase in expression due to the inhibition of miR-181a in HepG2 cells could 
mean that inhibiting miR-181a leads to a mechanism in HepG2 cells that may decrease 
cancer cell growth and progression.  
The Western blot results of these proteins that were probed for generally coincide with the 
LC-MS/MS data in terms of the trends of the proteins’ expression when transfected with 
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the various miRNAs. However, it can be seen that the extent of change in expression 
levels are different from that of the LC-MS/MS results. This could be due to the 
differences in both types of quantification methods. The Western blot generally involves 
less processing and whole proteins are probed using antibodies while the iTRAQ-related 
LC-MS/MS requires much more processing prior to the actual identification and 
quantification of the proteins. Ideally, the processing of samples should not affect the 
protein levels, but the accumulation of errors in the processing steps may lead to a larger 
than necessary difference observed. Not only that, but the detection of proteins (eg. 
Specificity and sensitivity) in the mass spectrometer is dependent on the limitations and 
parameters set on the equipment, some of which cannot be controlled by the end user. 
Because of these reasons, a difference in the expression levels of proteins is expected. 
Despite this, the LC-MS/MS still remains to be a very useful tool in establishing a protein 
profile for subsequent analyses to be performed.    
Gathering all the results obtained from the LC-MS/MS as well as Western blot analyses, 
the primary information obtained is that miR-181a may act as an oncogene in HepG2 cells. 
Inhibiting it, on the other hand, could possibly lead to an activation of pathways that are 
anti-proliferative. With this hypothesis in mind, we proceeded to conduct a cell viability 
test on HepG2 cells transfected with miR-181a as well as its inhibitor. 
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Figure 15. Western blot validation of LC-MS/MS results. HepG2 cells were transfected with miR-181a and its 
inhibitor and incubated for 24h and probed with various selected primary antibodies overnight at 4oC. miR-181a 
increased the expression of NPM1 while miR-181a inhibitor increased 14-3-3σ protein expression level and decreased 
NPM1 and Hsp-90β expression levels. β-actin served as a loading control. Brightness and contrast was adjusted to 
improve image clarity.   
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Figure 16. Quantification of Protein levels of 14-3-3σ, Hsp-90β and NPM1 in HepG2 cells. Proteins were quantified 
using Image J software. The densities of the individual bands on the Western blots were analysed by the software 
and quantified. The fold changes were then obtained by normalizing the values of samples obtained against those 
of the controls. Using a Student’s t-test, the protein levels of NPM1 protein was found to increase significantly 
when transfected with miR-181a (p value= 0.043) (n=3). Both NPM1 and HSP-90β was seen to decrease 
significantly (p value= 0.00027 and 0.000032 respectively) (n=3). 
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3.2.4 Inhibiting miR-181a Significantly Reduced HepG2 Cell Viability and Sensitizes it 
to Cisplatin Treatment 
 
Cell viability refers to the level of metabolism in cells and in some cases may extend to 
cell proliferation, because a proliferating cell generally has a higher metabolism than a 
resting cell. Cell viability assays measure the activity of cellular enzymes on their ability 
to reduce a tetrazolium dye to a coloured product (formazan) such that a colorimeter may 
be used to measure the concentration of coloured compounds formed. This gives a 
correlation of how active the cells are. Many cell viability assays have been developed 
using different types of dyes. In our study, we have chosen to use the Water soluble 
Tetrazolium salts (WST-1) assay. Among the assays available, this method is unique 
because the dye is reduced outside the cell, producing a soluble coloured formazan, so it 
does not require any addition of solubilizing reagents that may interfere with cell viability 
(unlike the other MTT assays). 
HepG2 cells were electroporated with 100nM miR-181a and its inhibitor respectively, 
seeded onto 96-well plates over 3 day period and cell viability assessed every 24h. In 
addition to transfecting cells with miRNAs, we also investigated whether miRNA 
transfection could work in combination with drug treatment. Current liver cancer therapy 
makes use of drugs and/or radiation. However, the main setback of these methods is the 
fact they cause the death of healthy, untransformed cells by causing unwanted side effects. 
Not only that, but many cancers adapt and become resilient towards drugs. These reasons 
limit the use of drugs in chemotherapy. As miRNAs are endogenous cellular compounds, 
they are less likely to cause an immune response and may be better received by cancer 
cells during therapy.  
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Cisplatin is a drug widely used in chemotherapy and mainly acts in causing cell apoptosis 
through irreversible binding to specific grooves in the DNA, rendering cells unable to 
undergo subsequent transcription and ultimately be programmed for apoptosis following 
cell cycle checks. Another mechanism in which it acts to lead to apoptosis is through its 
binding to important cellular proteins [106]. With that, we first tested the optimal cisplatin 
concentration to be used in the experiments. A serial dilution of cisplatin concentrations 
was carried out on HepG2 cells seeded in 96-well plates. 24h after cisplatin treatment, 
their cell viabilities were measured using the WST-1 assay. Figure 17 shows the 
viabilities of HepG2 cells 24h after exposure to various concentrations of cisplatin. 
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Figure 17. Growth curve of HepG2 cells treated with cisplatin. 30K HepG2 cells were seeded in each well of a 96-
well plate and treated with various doses of cisplatin. Cell viabilities were measured after 24h of drug incubation. 
21μg/μl cisplatin concentration was chosen as the experimental dosage because at this concentration, the cells are 
slightly weakened (35%) by the treatment but still viable enough for a WST-1 assay to work. 
HepG2 cell viability is observed to decrease as the cisplatin dosage increases. As we are 
interested in performing a WST-1 cell viability assay on cells both transfected with the 
miRNA and treated with cisplatin, the cells should not be totally killed off by the drug 
treatment. Instead, the drug should exert a slight, weakening effect on the cells such that 
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its effects are still felt. With that, 21μg/μl cisplatin was chosen as the experimental 
concentration, because the cells at this drug concentration are weakened (cell viabilities 
are lowered to approximately 65% of control cells after a 24h incubation) but are still 
viable so that any additional change in viabilities due to the miRNAs per se may be still 
studied.  
In the actual experiment, HepG2 cells were first transfected with the miRNAs and then 
incubated for 24h, 48h and 72h before treating them with 21μg/ml cisplatin for 24h. This 
‘transfect-then-treat’ procedure was chosen over the ‘treat-then-transfect’ as the treatment 
of cells initially with cisplatin could mask the effects induced by subsequent transfection 
of cells with the miRNAs. Also, transfecting the cells firstly with the miRNAs would 
enable them to express the different proteins which may sensitize or desensitize the cells 
to drug treatment. Results of this experiment are shown in Figure 18. 
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Figure 18. Comparison of miRNA-transfected HepG2 cell viabilities with and without cisplatin treatment. HepG2 
cells were either transfected only with 100nM miR-181a/miR-181a inhibitor or subsequently treated with 21μg/ml 
cisplatin for 24h and their viability assessed via WST-1 assay. The different time points refer to the amount of 
incubation time of HepG2 cells post-transfection (pre-treatment). Absorbance readout of dye generated by assay was 
measured at 450nm. At the 24h time point, an increase in cell viablity in both cases (ie. Cells transfected with miR-181a 
only and cells tranfected as well as treated with cisplatin) (p value=0.0002 and 0.0024 respectively) were detected as 
compared to cells transfected with the control miRNA. Cell viability at 24h was seen to increase by about 20-30% for 
HepG2 cells transfected with miR-181a as compared to the control miRNA, both with and without cisplatin treatment. 
Conversely, there is a significant decrease of 20% in HepG2 cell viablity in both cases when transfected with miR-181a 
inhibitor (p value=0.0015), with a slight further decrease in viability (p value=0.0009) upon cisplatin treatment, leaving 
only 80% of viability measured as compared to that of the control samples. (n=3) 
 
The transfection of miR-181a causes a significant increase in HepG2 cell viability by 
approximately 20% (p value= 0.0002) while inhibiting it reduces cell viability by a similar 
amount (p value=0.0015) at a 24h incubation period. At longer incubation periods of 48-
72h, HepG2 cells transfected with miR-181a displayed a level of viability comparable to 
that of the control sample. This could be due to the fact that the transfection was transient 
in nature, therefore the cells that were present at longer time intervals (ie. 48-72h) could 
have been diluted with non-transfected cells (ie. Offspring of the original batch of cells), 
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therefore skewing the viabilities towards that of the control samples. This is very possible, 
since miR-181a causes an increase in cell viability/proliferation, thereby increasing the 
chances of such a dilution. The slight decrease in miR-181a expression levels after 24h 
could have also led to the drop in cell viability. Transfecting the cells with miR-181a 
inhibitor though, causes a sustained drop in cell viability through 72h of incubation, 
hovering that around 80% even at 72h post-transfection. Again, this could be due to the 
decrease in cell metabolism because of the inhibition of miR-181a, which could have led 
to a slowdown in cell proliferation, therefore the cells are ‘less diluted’ and their viability 
readouts do not skew towards that of the control samples as quickly. It would be expected, 
after a longer incubation time, for all the viabilities of all the samples to be similar to each 
other.  
The treatment of HepG2 cells with cisplatin following the transfection of miR-181a 
inhibitor resulted in a further decrease in cell viability at a 24h incubation period as 
compared to the control (p value=0.0009). The same experiment carried out with miR-
181a shows an increase in HepG2 cell viability (p value= 0.002). These results suggest 
that miR-181a desensitizes HepG2 cells while inhibiting miR-181a sensitizes them 
towards cisplatin treatment. The previous LC-MS/MS study could give some explanation 
to this observation. The LC-MS/MS identified and quantified Hsp-90β as a protein down-
regulated while 14-3-3σ was up-regulated in HepG2 cells by the transfection of miR-181a 
inhibitor. Further analysis with Western blot confirmed this observation. The lowered 
expression of Hsp-90β, along with the increased expression of 14-3-3σ with the 
transfection of miR-181a inhibitor may be one of the modes in which inhibiting miR-181a 
works in reducing HepG2 cell viability, as confirmed with the WST-1 assay where 
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viability was found to be reduced by approximately 20% 24h post-transfection. The 
increase in 14-3-3σ protein could possibly have weakened the more active cells from 
proliferating by causing an initial cell cycle arrest, leading to lowered cell viability as 
compared to control cells. 
In addition, cancer cells are more resistant in the face of extreme environmental stress, for 
example, during chemotherapy or radiation. These stresses generate free radicals that may 
cause substantial physical damage to cellular proteins that are normally protected by Hsp-
90β [99]. The decreased expression of Hsp-90β may explain the further decrease in cell 
viability by sensitizing HepG2 cells to cisplatin treatment, as there would be less 
protection for cells and more damage done to cellular proteins due to the drug, leading to 
further lowered cell viability. Results of this experiment show that a combination of drugs 
and miRNAs could potentially be used as a better treatment option instead of solely 
relying on the use of drugs, as issues of drug-related resistance and/or toxicity may be 
addressed as compared to traditional chemotherapy. Drug dosages may be lowered when 
in use with appropriate miRNAs in treatments as well.  
Also in our study, the transfection of miR-181a and its inhibitor led to an increase and 
decrease in NPM1 expression levels respectively.  The increase in NPM1 when 
transfected with miR-181a could have possibly contributed to HepG2 cells with increased 
viability. The decrease in NPM1, on the other hand, could have reduced the cells’ ability 
to inhibit apoptosis, therefore enabling the action of cisplatin to work better, thereby 
further reducing the cells’ viabilities slightly more. The results from these experiments all 
suggest that inhibiting miR-181a could potentially play a tumour suppressive role in HCC. 
92 
 
3.2.5 Inhibiting miR-181a Delays HepG2 Cell Cycle Progression  
 
As cell growth has been shown in our studies to be affected by the transfection of HepG2 
cells with miR-181a and its inhibitor, we next investigated if miR-181a has any influence 
on cell cycle progression. HepG2 cells were transiently transfected with miR-181a, miR-
181a inhibitor as well as their corresponding control miRNAs. Prior to transfection, they 
were synchronized by serum deprivation overnight. Serum starvation is one of the few 
cell synchronisation methods used in cell cycle analysis. Its rationale works on the basis 
that cells deprived of growth nutrients are forced into quiescence, therefore they would 
theoretically be at the same ‘starting point’ at the actual commencement of the experiment. 
Certainly, it does not come without its disadvantages, one being that it may pose as a form 
of stress for the cells if the cells are starved beyond a certain time point. Another method 
that may be used is via chemically reversible inhibitors to arrest the cells at specific stages 
of the cell cycle. This poses similar problems as serum starvation in that their over-
exposure may cause unwanted side effects, and could potentially be even more than that 
of serum starvation due to the introduction of an exogenous compound to the cell 
population. Other methods exist but are more complicated, for example, the mitotic shake-
off method or using centrifugal elutriation. Again, they each have their own drawbacks, 
the first having a low yield (of synchronised cells) and the second requiring special rotor. 
Taking into consideration these options and their respective drawbacks, we chose to use 
serum starvation as our method of choice due to its relative simplicity in carrying out and 
proven use in the literature. Whether or not this method of synchronization worked was 
not quantitatively verified here, partially due to the fact that it has previously been 
validated to work by other studies. However, on our part, it was noted by eye that the 
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HepG2 cells were growing at a much slower rate during the starvation period, very much 
visibly different from when they were exposed to 10% FBS. This was a good sign that 
they could be all slowing down in cell cycle. Also, at the end of the overnight incubation, 
there was little or no detachment of cells, meaning that the starvation was not too harsh 
such that cells started to detach from the surface.   
24h post-transfection, the cells were harvested, fixed and sent for flow cytometry analysis 
using propidium iodide staining (PI). PI is a fluorescent molecule that is able to bind to 
double stranded nucleic acids. Therefore, with proper treatment with ribonucleases 
(RNases), it is able to quantify the amount of DNA in cells. As cells enter the various 
phases in the cell cycle, the amount of DNA changes, doubling as it enters S phase. Hence, 
the amount of DNA detected by PI corresponds to the proportion of cells undergoing cell 
cycle.     
Results of the cell cycle analysis (Figure 19 and Table 6) show that inhibiting miR-181a 
delays cell cycle entry by about 10% while miR-181a has the opposite effect of promoting 
it, albeit to a lesser extent. Inhibiting miR-181a significantly increased the proportion of 
HepG2 cells in the G1 phase (p value= 0.0352) and reduced that of cells in the S and 
G2/M phases (p value= 0.0399) while the opposite was seen in the case of miR-181a 
transfection. This may explain why cells were seen to be more viable due to the 
transfection of miR-181a, as the entry into cell cycle could have indicated an increase in 
metabolism and/or increased cell proliferation by encouraging cells to go into DNA 
synthesis and subsequent mitosis. However, as the effect of miR-181a on cell cycle entry 
was not found to be statistically significant in this experiment, a more probable reason 
behind the increase in cell viability as seen in the previous cell viability test could have 
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been due to the increase in metabolic state of the cells instead of an increase in cell 
proliferation per se.  Conversely, the delay in entering cell cycle caused by the 
transfection of miR-181a inhibitor could have slowed down HepG2 cell growth, thereby 
rendering the cancer cells to be less active and/or proliferative.  
 
Figure 19. HepG2 cells transfected with miRNAs and analysed by flow cytometry. Panels A, B, C, D represent the 
cell cycle plots of HepG2 cells transfected with the mimic control, miR-181a, inhibitor control and miR-181a inhibitor 
respectively. Serum starved cells were harvested 24h post-transfection. Percentages of cells in G1, S and G2/M phases 
are indicated in Table 6. MiR-181a inhibitor significantly delayed cell cycle progression by increasing the proportion of 
cells in the G1 phase (p value= 0.0352) and significantly decreasing the cells in S phase (p value= 0.0399) (n=3). 
 
Table 6.% of HepG2 cells in G1, S and G2/M phases of the cell cycle after transfection with various miRNAs.  
 Table 6. % of cells in the respective cell cycle phases (Mean±SD) 
Cell phase A 
miR-mimic control 
B 
miR-181a mimic 
C 
miR-inhibitor control 
D 
miR-181a inhibitor 
G1 62.5 ± 3.67 
 
56.8 ± 7.07 
 
 
48.3 ± 8.71 
 
 
60.4 ± 3.33 
 
 
S 19.7 ± 4.49 
 
 
24.9 ± 5.32 
 
 
28.4 ± 2.79 
 
 
20.8 ± 5.04 
 
 
G2/M 19.1 ± 4.98 
 
 
19.6 ± 3.08 
 
24.9 ± 8.06 
 
19.1 ± 1.32 
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3.2.6 Section Conclusion 
 
Our results so far suggest that inhibiting miR-181a in HepG2 cells significantly lowers 
cell viability. This could possibly be through the increased expression of a number of 
important tumour suppressors like 14-3-3σ, as well as the decrease in other oncoproteins 
like Hsp-90β and NPM1. 14-3-3σ acts by activating p53 while the decrease of both Hsp-
90β and NPM1 leads to a decrease in cellular protection in general, enhancing the action 
of cisplatin when the cells were subsequently treated with the drug. Cell cycle was also 
seen to be delayed. On the other hand, miR-181a increases the expression of tumour 
causing proteins like NPM1, leading to the observed increase in cell viability. Inhibiting 
miR-181a attenuates HCC through various pathways, and this should not be surprising as 
miRNAs are known to be unspecific, hence their presence in cells affects not just one, but 
numerous proteins and their subsequent pathways. This is useful in cancer therapy as most 
cancers have not just one or a few mutations, but thousands of mutated genes and 
pathways that using specific drugs or siRNAs prove to be insufficient in resulting in its 
eradication. In this first study, we see an overall anti-proliferative and tumour suppressive 
role when miR-181a is inhibited in HepG2 cells, while miR-181a itself results in HepG2 
cells being more viable and less sensitive towards cisplatin treatment. The use of miR-
181a inhibitor in HCC could potentially aid in eliminating more cancer cells.  
4. Role of MicroRNA-181a in HepG2 Cells: Its Cell Cycle Targets  
4.1 Introduction 
 
The first section of this project elucidated an overall picture of the effects of 
overexpressing and inhibiting miR-181a in HepG2 cells. To gain a further understanding 
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of the functions of this miRNA, an in-depth molecular study on the direct targets of miR-
181a will be investigated in this section. MiRNAs are generally known to perform their 
regulatory function through their binding to the 3′-UTRs of target mRNAs, ultimately 
leading to a repression of target protein expression levels. However, miRNAs, being non-
specific in nature, are able to bind to multiple mRNAs in the cells and in the process, 
regulate many proteins simultaneously. Not only that, but because they usually bind with 
partial complementarity to mRNAs, it makes it more difficult to identify the direct targets 
of miRNAs. Nevertheless, we make use of bioinformatics as our first mode of narrowing 
down the choices of putative targets. From there, with our chosen targets, we carry out 
wet lab experiments to validate the targets both in vitro and in vivo.   
4.2 Results and Discussion 
4.2.1 Bioinformatics Screening of Putative mRNA Targets 
 
Bioinformatics has evolved over the years and is now an important tool in generating new 
biological knowledge.  It is an interdisciplinary field that develops and improves upon 
methods for storing, retrieving, organizing and analysing biological data. It plays many 
roles in biology, ranging from sequencing and annotating genomes, image and signal 
processing, organizing biological data, the analysis of gene and protein expression and 
regulation, etc. Of course, it is also involved in structural biology, aiding the simulation 
and modelling of DNA, RNA, and protein structures as well as molecular interactions. We 
thus make use of bioinformatics as a platform to help us identify possible mRNA targets 
of miR-181a based on sequence complementarity as well as mRNA folding.  Three online 
software and databases, namely, TargetScan 6.2, miRanda and PicTar, were used in the 
first step to elucidate potential mRNA targets of miR-181a. Putative targets that were 
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predicted in at least two of the software were chosen for further study. Additionally, 
among the many possible targets predicted and listed, those that are involved in important 
cancer-related processes were selected for subsequent wet lab analysis. Two such targets 
of interest are cyclin-dependent kinase inhibitor 1B (CDKN1β) and transcription factor 
E2F7 (E2F7).  Figures 20 through 22 show the putative binding sites and binding scores 
of miR-181 family to the 3’ UTRs of CDKN1β and E2F7 based on TargetScan, miRanda 
and PicTar respectively. The locations of the predicted binding sites are similar for the 
three independent software.  
 
 
Figure 20. TargetScan’s predicted binding sites of miR-181a to the 3’UTRs of CDKN1β and E2F7. The total 
context score is based on six features: site-type contribution, 3' pairing contribution, local AU contribution, position 
contribution, TA (target site abundance) contribution and SPS (seed-pairing stability) contribution. The more negative 
the context score, the higher the probability of mRNA binding. The probability of conserved targeting, PCT, refers to the 
likelihood of the sequence being conserved so as to allow regulation by the miRNA. The higher the PCT, the higher the 
chance of miRNA:mRNA binding. 
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Figure 21. MiRanda’s predicted binding sites of miR-181a to the 3’UTRs of CDKN1β and E2F7. The mirSVR 
score is based on seed-site pairing, site context, free-energy, and conserved targeting. The more negative the mirSVR 
score, the higher the probability of mRNA binding. PhastCons score refers to the likelihood of the sequence being 
conserved so as to allow regulation by the miRNA. The higher the PCT, the higher the chance of miRNA:mRNA binding. 
 
Figure 22. PicTar's predicted binding site of miR-181a to the 3’UTR of E2F7. Similar to TargetScan, PicTar also 
predicts miRNA-mRNA interaction based on identical seed sequences. The PicTar algorithm score is based on seed 
complementarity, thermodynamics and a combinatorial prediction for common targets in sets of co-expressed miRNAs. 
There was no prediction for the binding of miR-181a to the 3’UTR of CDKN1β mRNA. 
According to TargetScan 6.2, the more negative the context score of an interaction, the 
more favourable it is for binding to occur. The context score is based on six types of 
interactions found both at the seed region and around the seed region. It seems that there 
is a more extensive base pairing between miR-181a and E2F7 as compared to CDKN1β 
due to the presence of predicted base interactions beyond the seed region, leading to a 
more negative context score. This same result was seen in miRanda as well, where the 
mirSVR score is more negative in the binding of miR-181a to the 3’UTR of E2F7 than 
CDKN1β mRNA. 
Not only is binding at the seed region crucial, but the way the mRNAs fold, especially at 
areas around the seed region, also plays a part in miRNA accessibility and binding.  
Secondary structures of mRNA may prevent miRNA targeting (if too much steric 
hindrance is present), even though their sequences may support a positive interaction. We 
next performed another bioinformatics study on the possibility of RNA folding around the 
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seed regions of the two binding sites identified. To do this, we make use of the public 
software ‘The Mfold Web Server’ [107]  to elucidate the structure of the RNAs at the site 
of binding. Figure 21 shows the possible predicted secondary structures of CDKN1β and 
E2F7 mRNAs at their binding regions to miR-181a.  
 
Figure 23. Predicted secondary structures of CDKN1β and E2F7 around the binding regions of miR-181a. Both 
structures are predicted to possess some RNA folding, but it does not appear to cause much steric hindrance at areas 
around the seed regions.  
Some RNA folding is predicted around the areas surrounding the binding regions between 
miR-181a and both the CDKN1β and E2F7 mRNA 3’UTRs. However, it does not appear 
to cause much steric hindrance as the structures look open, with no major blockage near 
the predicted interaction sites. As this was just carried out as a brief, qualitative analysis 
on the 3’ UTRs of the two mRNAs around their specific sequences of interest, it does not 
take into account the possible hindrance that may stem from further upstream or 
downstream sequences along the same mRNA that may be present in the cellular 
environment. However, as a first step and with the preliminary RNA structures we have 
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obtained, we shall assume that these two binding regions are open for miRNA binding. 
Therefore, using information from our bioinformatics study as the first step, we proceeded 
to validate for any actual binding between the two RNAs. 
4.2.2 In vitro Binding of miR-181a to the 3’UTR of CDKN1β and E2F7 via Surface 
Plasmon Resonance 
 
Based on the results of the bioinformatics analysis, we proceeded to use SPR to monitor 
miR-181a:mRNA interactions, if any. Single-stranded RNA and DNA nucleotides 
carrying the putative binding 3’UTR seed regions and flanking nucleotides were 
synthesized and immobilized in separate flow channels. Although we are interested in 
studying the interactions between mRNAs and miR-181a, because of the inherent 
instability of RNAs as opposed to DNAs, we also incorporated the DNA version of the 
synthesized nucleotides in our study, with the only difference being that the DNA strands 
contain deoxyribose instead of a ribose unit. The sequences in the synthesized DNA is the 
exactly the same as that of the RNA, both containing only the AUGC nucleotides. This 
served as a type of control in case of any RNA degradation during the experiment. 
Synthesized miR-181a at different concentrations was subjected in a single run.  Kinetic 
binding constants were determined. Sensorgrams for the two flow channels containing the 
binding portions of the 3’UTRs of CDKN1β and E2F7 RNA shows that they both 
interacted significantly with miR-181a. As shown in Figure 22, the experimental curves of 
the binding between miR-181a and CDKN1β and E2F7 fit closely to a 1:1 binding model 
(Panels A and C). The slight discrepancy between the theoretical and experimental curves 
is likely to be due to the aggregation of miR-181a at high concentrations. The dissociation 
constants (KD) for the binding between miR-181a and CDKN1β and E2F7 are 272.5 ± 
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0.008 nM and 1.186 ± 0.009
 
uM respectively, indicating that the binding between miR-
181a and CDKN1β is stronger than that with E2F7, although a more extensive binding 
was predicted between miR-181a and E2F7. Both DNA versions of the synthesized 
oligomers, on the other hand, did not show any in vitro binding with miR-181a (Panels B 
and D). The deoxyribose unit in the backbone may have caused a change in oligo 
structure and positioning as compared to its ribose counterpart, such that binding to miR-
181a is impossible.  
   
  
Figure 24. Experimental curves of the bindings between miR-181a and CDKN1β and E2F7 (both RNA and DNA 
backbone). A positive 1:1 binding is observed between both miR-181a and CDKN1β (RNA) and E2F7 (RNA) (Panels 
A and C) with dissociation constants 272.5 ± 0.008 nM and 1.186 ± 0.009 uM respectively. The DNA versions of 
CDKN1β and E2F7 (Panels B and D) did not show any binding to miR-181a. 
PANEL A 
CDKN1β (RNA) 
 
PANEL B 
CDKN1β (DNA) 
 
PANEL D 
E2F7 (DNA) 
 
PANEL C 
E2F7 (RNA) 
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4.2.3 In vivo Binding Confirmation of miR-181a to the 3’UTR of CDKN1β and E2F7 
 
The successful detection of interaction between miR-181a and the two seed regions (and 
the sites flanking them) of the 3’UTRs of CDKN1β and E2F7 mRNAs in vitro next led us 
to study if the interactions are also positive in the cellular environment. As the cellular 
environment is very much different from that in vitro, in order to ensure that positive 
binding occurs between the miR-181a and the mRNAs in cells, we investigated the 
binding via a luciferase assay.   
Results (Figure 23) show that miR-181a binds to both the 3’UTRs of CDKN1β and E2F7 
in HepG2 cells, confirming the previous findings of in vitro binding. A tenfold dilution of 
miR-181a was studied and in general, it seems that miR-181a does bind to the control 
plasmid to an extent, because the normalised firefly luciferase activity was lowered as the 
concentration of miR-181a increased from 10nM to 100nM. However, comparing data 
within the same miR-181a concentration shows that miR-181a binds to a larger extent to 
the 3’ UTRs of CDKN1β and E2F7 mRNAs as compared to the control plasmid, evident 
from the decrease in firefly luciferase activity detected. Not only that, but it seems that in 
vivo, miR-181a binds more strongly to the 3’ UTR of E2F7 than of CDKN1β mRNA. 
This is in contrast with the results of the in vitro SPR experiment, which demonstrated 
positive miR-181a binding to both seed region sequences of the two mRNAs, but more 
strongly towards that of CDKN1β instead of E2F7. It could be that the cellular 
environment was able to facilitate further, the binding of the miRNA to the 3’UTR of 
E2F7, due to the presence of various enzymes and RNA-induced silencing complex 
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(RISC) that could aid strengthening the bond between miR-181a and the 3’UTR of E2F7, 
or that the ionic concentration in vitro had affected binding affinity. A more extensive 
binding between miR-181a and E2F7 was also previously predicted as compared to that of 
CDKN1β by bioinformatics analysis. In any case, miR-181a seems to target both mRNAs 
significantly, with p values= 0.0022 and 0.0008 for 100nM miR-181a targeting the 
3’UTRs of CDKN1β and E2F7 respectively, and p values= 0.0057 and <0.0001 for 10nM 
miR-181a targeting the 3’UTRs of CDKN1β and E2F7 respectively.  
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Figure 25. In vivo luciferase assay study of HepG2 cells co-transfected with the reporter plasmids and different 
concentrations of miR-181a. HepG2 cells were electroporated with 4μg of reporter plasmids and 10nM or 100nM 
miR-181a and seeded on 24 well plates. They were harvested after a 24h incubation and assayed for firefly and renilla 
luminescence using a manual luminometer. Results show that miR-181a binds to some extent, to the control vector, 
because of its dose dependent reduction in firefly luciferase activity upon transfection with the control vector. However, 
as compared to the control, miR-181a shows a significantly stronger binding to both the plasmids containing the 
3’UTRs of CDKN1β and E2F7, with a further decrease in firefly luciferase activity by about two times when transfected 
with 10nM miR-181a (p value= 0.0057 and <0.0001 respectively) (n=3) and up to six times when transfected with 
100nM miR-181a (p value= 0.0022 and 0.0008 respectively) (n=3), as compared to when transfected with the control 
reporter plasmid. 
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4.2.4 Western blot Verification  
 
Binding of miR-181a to the 3’UTRs of CDKN1β and E2F7 in vivo may result in either the 
degradation of the mRNAs, the translational inhibition of the mRNAs to proteins or the 
temporary storage of the mRNAs in processing bodies (P-bodies) of cells and ultimately 
either degraded or released for delayed translation [108]. To study whether the protein 
levels of CDKN1β and E2F7 are affected by the transfection of miR-181a, we performed 
a Western blot analysis. Figures 24 and 25 show that the transfection of 10nM miR-181a 
downregulates the protein levels of CDKN1β and E2F7, but only the protein levels of 
E2F7 was statistically shown to be significantly downregulated (p value= 0.03). These 
two proteins were chosen in this study because our previous findings indicate that miR-
181a, a miRNA found upregulated in HCC, causes a significant increase in HepG2 cell 
viability and may also play a part in cell cycle. These two proteins have been predicted by 
bioinformatics to be potential targets of miR-181a, and both partake in the negative 
regulation of the cell cycle and proliferation. CDKN1β is a well-known protein that 
prevents the activation of cyclin E-CDK2 and cyclin D-CDK4 complexes, thereby leading 
to a G1 cell cycle arrest [109]. E2F7 is a relatively newly discovered member of the E2F 
family of transcription factors that are highly involved in cell cycle progression, DNA 
repair and mitosis. In contrast to other well-studied E2F transcription factors (eg. E2F1, 
E2F2 and E2F3), E2F7 acts in the cell cycle by being a transcriptional repressor and 
negatively regulates cell proliferation [110]. The downregulation of these two proteins by 
miR-181a could have been one of the reasons that led to the increase in HepG2 cell 
growth as seen in our previous study. We also notice that miR-181a downregulated E2F7 
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protein more than CDKN1β. This is in line with the luciferase results obtained, where it 
was shown that a stronger binding occurred between miR-181a and the 3’UTR of E2F7. 
Also, in the earlier bioinformatics study, it was predicted that miR-181a forms a more 
extensive interaction with the 3’UTR of E2F7 than CDKN1β. Not only that, but the Mfold 
results on RNA folding also showed a more negative free energy of folding (ΔGfold) at the 
binding region between miR-181a and the 3’UTR of CDKN1β, indicating a possibility of 
more secondary structures there. In this section, we show that miR-181a targets both 
mRNAs, but binds to the 3’UTR of E2F7 and downregulates its protein to a larger extent.  
 
Figure 26. CDKN1β and E2F7 protein expression levels detection via a Western blot analysis. HepG2 cells were 
starved, electroporated with 10nM miR-181a and harvested after 24h incubation. 30μg total protein extract was loaded 
onto each well of an SDS-PAGE and probed with various selected primary antibodies overnight at 4oC. Mir-181a 
reduced the protein expression levels of both CDKN1β and E2F7; with the reduction of E2F7 to a greater extent. β-actin 
served as a loading control.  
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Figure 27. Protein levels of CDKN1β and E2F7in HepG2 cells following miR-181a transfection. Quantification of 
protein levels was analysed using Image J software. The transfection of miR-181a into the cells seems to decrease the 
amounts of these two proteins, but only the protein expression of E2F7 was statistically significant. ANOVA analysis of 
the three groups (done separately for each protein) showed a difference in means for that of E2F7 but not CDKN1β (p 
value= 0.03) (n=3). On closer inspection with a Student’s t-test, the levels of E2F7 is shown to be significantly 
decreased when the cells were transfected with miR-181a as compared to the control (p value= 0.03) (n=3). 
 
4.2.5 Section Conclusion 
 
MiR-181a is found to target cell cycle proteins CDKN1β and E2F7. Their interactions 
were shown to be positive both in vitro and in vivo, using SPR and luciferase assays to 
validate respectively. However, a positive binding does not necessarily lead to protein 
downregulation. Although miRNAs are known to bind to mRNAs and affect protein 
levels, the exact mechanisms of protein regulation is still not well understood. The general 
consensus is that miRNAs bind to mRNAs and cause either mRNA degradation or a 
protein translation. However, there are also studies that show that the mRNAs may be 
temporarily stored and translated at a later time; the protein may still be expressed, albeit 
delayed. Also, because of the non-specific nature of miRNAs, binding to a certain mRNA 
may decrease the protein expression due to that particular binding. However, other 
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pathways and transcriptional factors activated by the same miRNA may cause an opposite 
effect of increasing transcription and/or stabilization of the target mRNA/protein. 
Therefore, the study of miRNAs is not as direct as we would like it to be. In order to study 
whether the proteins of the two target mRNAs are affected by miR-181a, a Western blot 
analysis was conducted. A slight, statistically insignificant downregulation of CDKN1β 
protein was observed while E2F7 protein appeared to be affected more, possibly due to 
the stronger binding between miR-181a and its 3’UTR. From this section, we have found 
that miR-181a plays a role in cell cycle by targeting cell cycle genes. This could be one of 
the reasons as to why cell viability was seen to be affected. We next look at other 
important pathways that this miRNA affects in a cell.  
5. MiR-181a in Cancer Related Pathways: Its Effect on Important 
Transcription Factors 
 
5.1 Introduction 
 
As we are interested in how miR-181a is involved in liver cancer, we expanded the 
investigation to include not just its direct targets, but also how it affects the expression or 
activity levels of important transcription factors involved in cancer. Because many such 
proteins are implicated, the most efficient method of evaluation would be via a microarray 
analysis. The main advantage of using microarrays is in its ability to examine large 
amounts of biological material because of its high throughput.  
Each of the ten reporter assays used in this microarray consists of a mixture of an 
inducible transcription factor responsive firefly luciferase reporter and a constitutively 
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expressing Renilla construct. The negative control consists of a mixture of a non-inducible 
responsive firefly luciferase reporter and a constitutively expressing Renilla construct, 
while the positive control consists of a mixture of constitutively expressing GFP construct, 
constitutively expressing firefly luciferase reporter and a constitutively expressing Renilla 
construct.  
5.2 Results and Discussion 
 
5.2.1 MiR-181a Significantly Activated the MAPK/JNK Pathway while Inhibiting it 
Significantly Reduced HIF-Related Hypoxia 
 
The constructs, as described above, were dried-down to the bottom of each well of the 96-
well plate, resuspended in OPTI-MEM growth media and reverse co-transfected with 
miR-181a or its inhibitor. The dual-luciferase activities were measured 48h after 
transfection The normalised firefly:Renilla luciferase activity was then plotted for three 
independent experimental repeats. Figure 26 shows the effects of the transfection of miR-
181a and its inhibitor in the various cancer-related signalling pathways, normalized with 
readouts obtained from the transfection of HepG2 cells with a control miRNA. Pathways 
that are shown to be significantly up or downregulated will be further discussed. Among 
the ten pathways analysed, miR-181a causes the activation of activating protein 1 (AP-1) 
transcription factor most significantly (p value= 0.029), by approximately two folds, while 
inhibiting it abolished this observation. AP-1 is a transcriptional factor involved in the 
mitogen-activated protein (MAP) kinase signalling pathway.  It contains two components, 
c-Jun and c-Fos, which are both crucial regulators of liver tumour development. C-Jun has 
been shown to promote the growth of tumour through the positive regulation of cell-cycle 
(eg. Cyclin D1) or through the repression of its negative regulators (eg. p16) [111]. It is 
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also able to antagonize apoptosis in liver tumours. In addition to the increase in activity or 
expression levels of AP-1, other transcriptional factors were also shown to be affected by 
miR-181a in HepG2 cells. Transcription factors involved in NFκB, Myc and Hypoxia also 
showed an increase, albeit lowered significance, in transcriptional activities overall. These 
are signalling pathways often found activated in cancers. It should be noted that the three 
independent measured activity readouts of the transcription factor for the MAPK/ERK 
pathway, Elk-1/SRF, have produced a large standard deviation. It is also not shown to be 
statistically significant, although the general trend may seem like it is activated when 
transfected with miR-181a. On further inspection of the raw values obtained, it is noticed 
that one of the repeats had produced an abnormally large firefly luminescence readout, 
almost twice that of the average value recorded. The other two repeats were of ‘normal 
range’. This outlier could be due to various reasons: a rare abnormality in the construct 
such that the firefly reporter is more highly expressed than normal (eg. Promoter-related) 
or an unexpected change in environment that occurred in that particular well of the array 
that may have caused a sudden, acute activation of Elk-1/SRF. In either case, it would be 
safe to say that no conclusion may be drawn from our experiments for this particular 
pathway when miR-181a was transfected into HepG2 cells. 
One interesting observation though, is that we have shown that miR-181a binds to the 
3’UTRs of CDKN1β and E2F7 (and lowers their protein expression levels), and also that 
miR-181a transfection leads to an increase in AP-1 transcription factor activity, this could 
technically mean that miR-181a has a positive role to play in cell cycle. However, the 
pathway in the microarray analysis containing the E2F-DP1 transcription factor did not 
show any significant change as compared to the control sample. This could be due to the 
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concurrent activation of contradicting pathways following miR-181a transfection. From 
the microarray results, the transfection of miR-181a leads to the activation of TGF-β and 
Notch pathways, albeit of lowered significance. This translates to an increase in 
SMAD2/3/4 and RBP-Jk transcriptional activities, which has a cell cycle inhibition effect 
and growth arresting effect (in HCC) respectively [112, 113]. It is the overall balance of 
these different reinforcing and contradicting pathways that leads to the final outcome on 
the expression levels of the proteins. Indeed, our previous study showed that cell cycle 
was not significantly affected when miR-181a was transfected. However, the transfection 
of its inhibitor showed a significant slowdown in cell cycle by about 10%. The E2F 
transcription factor activity was seen to be lowered from the microarray study when miR-
181a was inhibited. 
In contrast to the increase in hypoxia-inducible factors (HIF) transcriptional activity by 
miR-181a, inhibiting it caused a corresponding significant decrease by approximately 40% 
(p value=0.027). Hypoxia is a condition in cells where oxygen concentration becomes low, 
leading to a massive transcription of genes by HIF proteins involved in angiogenesis, 
metabolism, cell proliferation and survival [114]. This is often seen in the case of many 
cancers, where oxygen concentration within cancer cells drop due to the spurt of cancer 
cell growth and HIF protein is overexpressed to accommodate this increase in cell 
proliferation. The lowered activity or expression levels of HIF in HepG2 cells transfected 
with miR-181a inhibitor could potentially decrease cell viability due to the reduction of 
this protective layer. Apart from the decrease in HIF, inhibiting miR-181a also caused a 
significant increase in SMAD protein activity (p value=0.0024). This protein is involved 
in TGF-β signalling, which can act as a tumour suppressor by causing a G1 cell cycle 
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arrest [112]. Also, the increase and decrease in p53 and E2F proteins may respectively 
contribute to the lowered cell proliferation and viability of HepG2 cells when transfected 
with miR-181a inhibitor. However, the significant activation of the NFκB pathway (p 
value=0.041), may negate some of the anti-proliferative effects of the other tumour 
suppressive pathways, due to the ability of the NFκB pathway to induce cancer-causing 
cellular alterations like increasing insensitivity to growth inhibition, self-sufficiency in 
growth signals, evasion of apoptosis immortalization, angiogenesis and metastasis [115]. 
This could also be the reason why inhibiting miR-181a showed a limited therapeutic 
effect when transfected into HepG2 cells in our previous study, where cell viability 
reduced by only 20%. The combination of miR-181a inhibitor with specific siRNAs to 
target such tumour-promoting proteins could potentially further increase the eradication of 
HCC.  Table 7 shows a summary of the transcription factors assayed and their roles in 
cancer.  
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Figure 28. Microarray analysis of the expression levels/activities of ten important cancer-related transcription 
factors. HepG2 cells were reverse co-transfected with 100nM miR-181a or 100nM miR-181a inhibitor, along with the 
dried down transcription factor reporter plasmids and incubated for 24h in 96-well plates. Cells were assayed for 
luciferase activity 48h after reverse transfection using a plate luminometer. The values plotted are that of firefly 
luminescence normalized against that of renilla, which was used as the internal control. Among the ten pathways 
investigated, miR-181a caused a significant activation in the MAPK/JNK pathway, as seen by the increase in expression 
levels/activity of AP-1 protein (p value= 0.029) (n=3). Inhibiting miR-181a significantly activated the NFκB (p value= 
0.041) (n=3) and TGF-β (p value= 0.0024) (n=3) pathways and lowered the HIF protein expression level/activity (p 
value= 0.027) (n=3). 
 
 
 
 
113 
 
Table 7. Transcription factors and their regulation by miR-181a and miR-181a inhibitor. The overall effects after 
regulation are listed alongside. Regulations in bold and labelled with an asterisk (*) refer to results that are significant. 
An increase in both tumour suppressive and tumour causing pathways are seen in both transfections. MiR-181a activates 
mainly tumour enhancing pathways while inhibiting it activates mostly tumour suppressive pathways.   
Transcription 
Factor 
Pathway(s) 
Involved 
miR-181a miR-181a Inhibitor 
Regulation Effect After 
Regulation 
Regulation Effect After 
Regulation 
TCF/LEF Wnt - - - - 
RBP-Jk Notch ↑ Growth Arrest - - 
p53 p53/DNA 
Damage 
- - ↑ Cell Cycle Inhibition 
SMAD2/3/4 TGFβ ↑ Cell Cycle 
Inhibition 
↑* Cell Cycle 
Inhibition 
E2F/DP1 Cell cycle/ 
pRb-E2F 
- - ↓ Cell Cycle Inhibition 
NFκB NFκB ↑ Insensitivity to 
growth 
inhibition, self-
sufficiency in 
growth signals, 
evasion of 
apoptosis 
immortalization, 
angiogenesis 
and metastasis 
↑* Insensitivity to 
growth inhibition, 
self-sufficiency in 
growth signals, 
evasion of apoptosis 
immortalization, 
angiogenesis and 
metastasis 
Myc/Max Myc/Max ↑ Proliferation - - 
HIF1A Hypoxia ↑ Survival/ 
Angiogenesis  
↓* Decreased Survival/ 
Angiogenesis 
Elk-1/SRF MAPK/ERK ↑ Proliferation - - 
AP-1 MAPK/JNK ↑* Positive Cell 
Cycle 
Regulation 
- - 
 
5.2.2 Section Conclusion 
 
As shown in the microarray analysis, miR-181a affects not just its direct targets but also, 
indirectly, many important transcription factors involved in cancer. This alone is sufficient 
in highlighting the impact miRNAs has in cells, and that their effects are not just limited 
to their protein targets alone. Ten cancer-related pathways were studied in HepG2 cells, 
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among which many of them were found to be affected by the overexpression of miR-181a 
or by its inhibition. MiR-181a causes a significant activation of the MAPK/JNK pathway 
by causing an increase in expression level or activity of AP-1 protein, a protein involved 
in positive cell cycle regulation and angiogenesis. It also causes activation of Hypoxia, 
MAPK/ERK, Myc, NFκB, TGFβ and Notch, but to a lesser extent for these. While the 
activation of MAPK/JNK, Hypoxia, MAPK/ERK, Myc and NFκB pathways directs the 
cell towards proliferation and survival, the simultaneous activation of TGFβ and Notch 
signalling leads the cell towards growth inhibition. MiR-181a seems to overall activate 
mainly the tumour-promoting signalling pathways probed for in the assay. 
Inhibiting miR-181a, on the other hand, causes a significant decrease in hypoxia and 
promotes cell cycle inhibition by decreasing and increasing HIF1A and SMAD2/3/4 
transcription factors respectively. It also causes a moderate increase of p53 and a 
corresponding decrease in E2F proteins. The overall effects of these tend to direct the cell 
towards a lowered cell proliferation. However, we also see a significant increase in the 
NFκB pathway, which has a counteracting effect by causing cells to become insensitive 
towards anti-growth signals.  
Our previous studies showed that miR-181a significantly increased HepG2 cell viability 
while inhibiting it significantly decreased cell viability, by approximately 20%. The 
regulation of these important cancer-related pathways could have contributed to the 
overall cell viability observed.  Because of the contradicting pathways activated when 
miR-181a was introduced or inhibited, the observed increase or decrease in viability was 
limited to a certain extent (ie. 20%). Specific targeting using siRNAs could aid in 
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deactivating pathways that enhance cancer cell growth, and the use of miRNAs and 
siRNAs could potentially improve current therapies in HCC.  
6. Identification of Other mRNA Targets of miR-181a: High 
Throughput Approach using Microarrays 
 
6.1 Introduction 
 
We previously identified two targets of miR-181a in HepG2 cells, namely, CDKN1β and 
E2F7. To do so, we employed bioinformatics as our first platform and then validated the 
results with SPR, luciferase assays and a Western blot analysis as described in Section 4 
of this thesis. In order to identify a larger range of targets, we made use of a custom-made 
microarray—miR-181 Targets RT2 Profiler PCR Array (Qiagen). In this microarray 
analysis, the expression of 84 hsa-miR-181a-5p target genes was profiled. This panel of 
84 genes includes currently known experimentally verified plus bioinformatically 
predicted target genes regulated by hsa-miR-181a-5p. The array also includes target genes 
regulated by other miRNAs that have the same seed sequence as hsa-miR-181a-5p, 
including hsa-miR-181b-5p, hsa-miR-181c-5p, hsa-miR-181d, and hsa-miR-4262. MiR-
181a target gene expression analysis provides further insight into the function of this 
miRNA. A set of controls present on each array enables data analysis using the 
ΔΔCT method of relative quantification as well as assessment of reverse transcription 
performance, genomic DNA contamination and PCR performance. Using real-time PCR, 
we analyse the expression of a focused panel of genes likely to be regulated by miR-181 
with this array. The array layout is shown in Table 8 and the full list of gene identification 
attached under the Appendix. 
116 
 
Table 8. Layout of miR-181 Targets RT2 Profiler PCR Array. 84 genes may be studied simultaneously in this array, 
along with five housekeeping genes, one genomic DNA contamination control, three reverse transcription controls and 
three positive controls. A real-time RTPCR approach will be used to study the gene expression of these selected genes 
in HepG2 cells transfected with miR-181a and its inhibitor.  
 
6.2 Results and Discussion 
 
6.2.1 BMPR2, GATA6, NOTCH4 and ZNF180 were among the 84 Genes Significantly 
Regulated by miR-181a or miR-181a inhibitor 
 
HepG2 cells were transfected with 100nM miR-181a or 100nM miR-181a inhibitor and 
incubated for 24h before harvesting for RNA extraction. Extracted RNA was reverse 
transcribed and allowed to undergo PCR in the microarray plate format as shown in Table 
6, with SYBR Green used as the reporter dye due to its ability to bind to double stranded 
DNA and its high sensitivity. Each run was done in triplicate. Figure 27 shows the typical 
amplification plot and melting curve obtained during each run of PCR.  
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Figure 29. Amplification Plot (left) and Melting Curve (right). The amplification plot shows the variation of log 
(ΔRn) with PCR cycle number, while a unique melting curve checks for specificity of the PCR product. 
 
Tables 9 and 10 show the fold changes and p values of the test samples (ie. HepG2 cells 
transfected with miR-181a or miR-181a inhibitor) vs control samples (ie. HepG2 cells 
transfected with control miRNA) for all the genes probed for in the microarray. P values 
in bold indicate significance (ie. P value<0.05). The overall changes in gene expression 
are represented as a 3D plot in Figures 28 and 29. 
Table 9. Fold change and p values of genes probed in HepG2 cells transfected with miR-181a. HepG2 cells were 
transfected with 100nM miR-181a, total RNA extracted and reverse transcribed. PCR was done on the cDNAs in the 
microarrays using SYBR Green as the reporter dye. ΔCt represents Ct(Gene of interest)-AvgCt(housekeeping genes), 
while the fold change is represented by ΔΔCt= 2^(- Delta Ct)) in the Test Sample divided the normalized gene 
expression (2^(- Delta Ct)) in the Control Sample. n=3 for each gene. 
Symbol Well AVG ΔCt               
(Ct(GOI) - Ave 
Ct (HKG)) 
2^-ΔCt Fold 
Change 
t-test Fold Up- or 
Down-
Regulation 
miR-
181aM 
Control 
Sample 
miR-
181aM 
Control 
Sample 
miR-
181aM 
/Control 
Sample 
p value miR-
181aM 
/Control 
Sample 
ACVR2A A01 8.32 8.57 3.1E-03 2.6E-03 1.19 0.267537 1.19 
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ADARB1 A02 5.45 5.91 2.3E-02 1.7E-02 1.37 0.457283 1.37 
ADCY1 A03 19.40 18.91 1.4E-06 2.0E-06 0.71 0.456841 -1.41 
AICDA A04 17.22 19.77 6.6E-06 1.1E-06 5.87 0.182613 5.87 
ATG5 A05 7.25 7.55 6.6E-03 5.3E-03 1.23 0.498072 1.23 
ATM A06 10.39 10.94 7.5E-04 5.1E-04 1.47 0.291322 1.47 
BCL2 A07 10.40 10.80 7.4E-04 5.6E-04 1.32 0.165535 1.32 
BCL2L11 A08 8.94 8.80 2.0E-03 2.2E-03 0.91 0.438811 -1.10 
BDNF A09 9.03 9.38 1.9E-03 1.5E-03 1.27 0.207232 1.27 
BMPR2 A10 8.16 8.87 3.5E-03 2.1E-03 1.64 0.019618 1.64 
C16orf87 A11 6.46 6.36 1.1E-02 1.2E-02 0.93 0.659065 -1.07 
C6orf62 A12 3.80 4.14 7.2E-02 5.7E-02 1.27 0.500807 1.27 
CAPRIN2 B01 9.16 9.49 1.7E-03 1.4E-03 1.26 0.485955 1.26 
CASP3 B02 7.47 5.95 5.7E-03 1.6E-02 0.35 0.313767 -2.86 
CBLB B03 8.42 9.09 2.9E-03 1.8E-03 1.59 0.402325 1.59 
CBX7 B04 10.77 11.23 5.7E-04 4.2E-04 1.37 0.840424 1.37 
CD69 B05 19.42 20.93 1.4E-06 5.0E-07 2.85 0.347530 2.85 
CDKN1B B06 5.24 5.46 2.7E-02 2.3E-02 1.17 0.540722 1.17 
CDX2 B07 17.64 14.34 4.9E-06 4.8E-05 0.10 0.373920 -9.86 
COPS2 B08 4.56 4.59 4.2E-02 4.1E-02 1.03 0.983017 1.03 
CXCR3 B09 15.80 17.23 1.7E-05 6.5E-06 2.69 0.091385 2.69 
CYLD B10 7.70 7.79 4.8E-03 4.5E-03 1.06 0.122809 1.06 
DDIT4 B11 6.84 6.31 8.7E-03 1.3E-02 0.69 0.443617 -1.44 
DISC1 B12 12.28 13.37 2.0E-04 9.4E-05 2.14 0.154479 2.14 
DOCK4 C01 12.18 12.82 2.2E-04 1.4E-04 1.57 0.540829 1.57 
DUSP5 C02 6.42 7.21 1.2E-02 6.7E-03 1.73 0.235421 1.73 
DUSP6 C03 9.63 8.72 1.3E-03 2.4E-03 0.53 0.404475 -1.88 
EIF4A2 C04 2.87 2.95 1.4E-01 1.3E-01 1.06 0.949822 1.06 
ENKUR C05 14.96 14.96 3.1E-05 3.1E-05 0.99 0.751036 -1.01 
ETV6 C06 7.53 8.11 5.4E-03 3.6E-03 1.49 0.140128 1.49 
FBXL3 C07 5.32 3.73 2.5E-02 7.5E-02 0.33 0.379105 -3.02 
FKBP1A C08 5.50 5.11 2.2E-02 2.9E-02 0.77 0.464486 -1.31 
FOS C09 8.19 8.37 3.4E-03 3.0E-03 1.13 0.829436 1.13 
GABRA1 C10 19.32 20.93 1.5E-06 5.0E-07 3.05 0.367941 3.05 
GATA6 C11 7.72 8.27 4.7E-03 3.2E-03 1.46 0.255139 1.46 
GLS C12 4.69 5.04 3.9E-02 3.0E-02 1.27 0.331817 1.27 
GRIA1 D01 20.78 17.44 5.5E-07 5.6E-06 0.10 0.373936 -10.13 
GRIA2 D02 20.78 18.01 5.5E-07 3.8E-06 0.15 0.371367 -6.82 
GRIK1 D03 12.89 13.84 1.3E-04 6.8E-05 1.93 0.071683 1.93 
HIPK2 D04 14.19 14.04 5.3E-05 5.9E-05 0.90 0.833027 -1.11 
HK2 D05 4.69 4.93 3.9E-02 3.3E-02 1.18 0.486988 1.18 
HMGB2 D06 4.07 4.30 5.9E-02 5.1E-02 1.17 0.392232 1.17 
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IGF1R D07 6.77 6.17 9.2E-03 1.4E-02 0.66 0.444346 -1.51 
IL1A D08 8.54 8.80 2.7E-03 2.2E-03 1.20 0.922057 1.20 
KANK1 D09 5.95 5.18 1.6E-02 2.7E-02 0.59 0.336143 -1.70 
KAT2B D10 8.75 8.71 2.3E-03 2.4E-03 0.97 0.980091 -1.03 
KCNA4 D11 18.40 18.23 2.9E-06 3.3E-06 0.89 0.820454 -1.12 
KIAA0195 D12 8.08 8.53 3.7E-03 2.7E-03 1.36 0.341902 1.36 
KLHL2 E01 8.15 8.27 3.5E-03 3.2E-03 1.09 0.589740 1.09 
KRAS E02 6.13 6.40 1.4E-02 1.2E-02 1.20 0.674682 1.20 
LRBA E03 7.65 7.98 5.0E-03 4.0E-03 1.26 0.447922 1.26 
MAP1B E04 9.48 9.75 1.4E-03 1.2E-03 1.21 0.627909 1.21 
MAP3K10 E05 8.14 8.83 3.5E-03 2.2E-03 1.62 0.269571 1.62 
MGMT E06 6.45 7.67 1.1E-02 4.9E-03 2.34 0.374145 2.34 
NARF E07 6.59 6.29 1.0E-02 1.3E-02 0.81 0.348006 -1.23 
NLK E08 7.80 8.08 4.5E-03 3.7E-03 1.21 0.654475 1.21 
NMT2 E09 8.20 7.67 3.4E-03 4.9E-03 0.69 0.323736 -1.45 
NOTCH4 E10 13.23 13.69 1.0E-04 7.5E-05 1.38 0.280996 1.38 
NPEPPS E11 5.88 5.96 1.7E-02 1.6E-02 1.06 0.849837 1.06 
PLAG1 E12 16.85 15.56 8.5E-06 2.1E-05 0.41 0.158431 -2.44 
PLAU F01 16.76 18.32 9.0E-06 3.1E-06 2.94 0.277788 2.94 
PLCL2 F02 6.90 5.96 8.4E-03 1.6E-02 0.52 0.320174 -1.91 
PRKCD F03 8.56 9.75 2.7E-03 1.2E-03 2.29 0.060598 2.29 
PROX1 F04 20.78 18.99 5.5E-07 1.9E-06 0.29 0.374823 -3.46 
PTPN11 F05 4.13 4.18 5.7E-02 5.5E-02 1.04 0.656689 1.04 
PTPN22 F06 14.13 10.42 5.6E-05 7.3E-04 0.08 0.373865 -13.05 
RALA F07 5.20 5.36 2.7E-02 2.4E-02 1.12 0.634097 1.12 
RLF F08 7.30 7.47 6.3E-03 5.6E-03 1.13 0.156487 1.13 
RNF2 F09 6.51 6.85 1.1E-02 8.7E-03 1.26 0.495303 1.26 
SIRT1 F10 6.76 7.00 9.3E-03 7.8E-03 1.18 0.701498 1.18 
SLC2A1 F11 4.62 4.75 4.1E-02 3.7E-02 1.09 0.436090 1.09 
STAT1 F12 2.73 4.64 1.5E-01 4.0E-02 3.75 0.169613 3.75 
TANC2 G01 6.98 7.29 7.9E-03 6.4E-03 1.23 0.940822 1.23 
TBPL1 G02 7.90 7.80 4.2E-03 4.5E-03 0.93 0.820814 -1.08 
TCERG1 G03 4.73 4.20 3.8E-02 5.4E-02 0.69 0.535745 -1.44 
TCL1A G04 16.76 15.85 9.0E-06 1.7E-05 0.53 0.693015 -1.88 
TMEM131 G05 6.44 6.78 1.1E-02 9.1E-03 1.26 0.318019 1.26 
VSNL1 G06 15.20 20.03 2.7E-05 9.4E-07 28.34 0.128277 28.34 
YTHDC1 G07 5.76 5.91 1.8E-02 1.7E-02 1.11 0.808541 1.11 
ZFP36L1 G08 4.34 3.76 4.9E-02 7.4E-02 0.67 0.409457 -1.50 
ZFP36L2 G09 4.68 4.22 3.9E-02 5.4E-02 0.73 0.461535 -1.38 
ZNF180 G10 7.79 8.10 4.5E-03 3.7E-03 1.23 0.257589 1.23 
ZNF37A G11 6.66 7.38 9.9E-03 6.0E-03 1.65 0.248678 1.65 
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ZNF83 G12 12.00 12.12 2.4E-04 2.2E-04 1.09 0.778311 1.09 
ACTB H01 -1.68 -2.17 3.2E+00 4.5E+00 0.71 0.280654 -1.41 
B2M H02 -0.21 0.02 1.2E+00 9.9E-01 1.17 0.634824 1.17 
GAPDH H03 -1.27 -0.92 2.4E+00 1.9E+00 1.28 0.722400 1.28 
HPRT1 H04 4.23 3.78 5.3E-02 7.3E-02 0.73 0.468227 -1.36 
RPLP0 H05 -1.07 -0.71 2.1E+00 1.6E+00 1.28 0.087210 1.28 
 
Table 10. Fold change and p values of genes probed in HepG2 cells transfected with miR-181a inhibitor. HepG2 
cells were transfected with 100nM miR-181a inhibitor, total RNA extracted and reverse transcribed. PCR was done on 
the cDNAs in the microarrays using SYBR Green as the reporter dye. ΔCt represents Ct(Gene of interest)-
AvgCt(housekeeping genes), while the fold change is represented by ΔΔCt= 2^(- Delta Ct)) in the Test Sample divided 
the normalized gene expression (2^(- Delta Ct)) in the Control Sample. n=3 for each gene. 
Symbol Well AVG ΔCt               
(Ct(GOI) - Ave Ct 
(HKG)) 
2^-ΔCt Fold 
Change 
t-test Fold Up- or 
Down-
Regulation 
miR-
181a 
inhibitor 
Control 
Sample 
miR-
181a 
inhibitor 
Control 
Sample 
miR-
181a 
inhibitor 
/Control 
Sample 
p value miR-181a 
inhibitor 
/Control 
Sample 
ACVR2A A01 8.16 8.57 3.5E-03 2.6E-03 1.33 0.178884 1.33 
ADARB1 A02 5.62 5.91 2.0E-02 1.7E-02 1.22 0.681159 1.22 
ADCY1 A03 19.15 18.91 1.7E-06 2.0E-06 0.85 0.927969 -1.18 
AICDA A04 19.09 19.77 1.8E-06 1.1E-06 1.60 0.575954 1.60 
ATG5 A05 7.43 7.55 5.8E-03 5.3E-03 1.09 0.881300 1.09 
ATM A06 10.52 10.94 6.8E-04 5.1E-04 1.34 0.432982 1.34 
BCL2 A07 10.47 10.80 7.0E-04 5.6E-04 1.25 0.191383 1.25 
BCL2L11 A08 8.81 8.80 2.2E-03 2.2E-03 1.00 0.949859 -1.00 
BDNF A09 9.41 9.38 1.5E-03 1.5E-03 0.98 0.883756 -1.02 
BMPR2 A10 8.14 8.87 3.6E-03 2.1E-03 1.66 0.261549 1.66 
C16orf87 A11 6.73 6.36 9.4E-03 1.2E-02 0.77 0.488151 -1.30 
C6orf62 A12 4.13 4.14 5.7E-02 5.7E-02 1.00 0.869187 1.00 
CAPRIN2 B01 9.43 9.49 1.5E-03 1.4E-03 1.05 0.822617 1.05 
CASP3 B02 7.70 5.95 4.8E-03 1.6E-02 0.30 0.294857 -3.36 
CBLB B03 8.53 9.09 2.7E-03 1.8E-03 1.47 0.532407 1.47 
CBX7 B04 9.99 11.23 9.8E-04 4.2E-04 2.35 0.185352 2.35 
CD69 B05 19.39 20.93 1.5E-06 5.0E-07 2.91 0.323067 2.91 
CDKN1B B06 5.77 5.46 1.8E-02 2.3E-02 0.81 0.430697 -1.24 
CDX2 B07 18.56 14.34 2.6E-06 4.8E-05 0.05 0.373911 -18.68 
COPS2 B08 4.75 4.59 3.7E-02 4.1E-02 0.90 0.658805 -1.11 
CXCR3 B09 17.18 17.23 6.7E-06 6.5E-06 1.04 0.792632 1.04 
CYLD B10 7.73 7.79 4.7E-03 4.5E-03 1.04 0.630303 1.04 
DDIT4 B11 7.21 6.31 6.8E-03 1.3E-02 0.54 0.405868 -1.86 
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DISC1 B12 12.76 13.37 1.4E-04 9.4E-05 1.53 0.256660 1.53 
DOCK4 C01 12.71 12.82 1.5E-04 1.4E-04 1.08 0.775658 1.08 
DUSP5 C02 6.66 7.21 9.9E-03 6.7E-03 1.47 0.468794 1.47 
DUSP6 C03 9.91 8.72 1.0E-03 2.4E-03 0.44 0.368368 -2.28 
EIF4A2 C04 3.65 2.95 7.9E-02 1.3E-01 0.62 0.192413 -1.62 
ENKUR C05 14.45 14.96 4.5E-05 3.1E-05 1.42 0.480452 1.42 
ETV6 C06 7.78 8.11 4.6E-03 3.6E-03 1.26 0.294626 1.26 
FBXL3 C07 4.82 3.73 3.5E-02 7.5E-02 0.47 0.417681 -2.13 
FKBP1A C08 5.36 5.11 2.4E-02 2.9E-02 0.84 0.570747 -1.19 
FOS C09 8.56 8.37 2.6E-03 3.0E-03 0.88 0.664234 -1.14 
GABRA1 C10 19.23 20.93 1.6E-06 5.0E-07 3.26 0.309785 3.26 
GATA6 C11 7.35 8.27 6.1E-03 3.2E-03 1.89 0.043807 1.89 
GLS C12 4.46 5.04 4.5E-02 3.0E-02 1.49 0.092393 1.49 
GRIA1 D01 19.43 17.44 1.4E-06 5.6E-06 0.25 0.377106 -3.95 
GRIA2 D02 17.50 18.01 5.4E-06 3.8E-06 1.43 0.502535 1.43 
GRIK1 D03 13.46 13.84 8.9E-05 6.8E-05 1.31 0.488462 1.31 
HIPK2 D04 13.78 14.04 7.1E-05 5.9E-05 1.20 0.620013 1.20 
HK2 D05 4.61 4.93 4.1E-02 3.3E-02 1.25 0.426343 1.25 
HMGB2 D06 4.16 4.30 5.6E-02 5.1E-02 1.10 0.548619 1.10 
IGF1R D07 6.95 6.17 8.1E-03 1.4E-02 0.58 0.410657 -1.72 
IL1A D08 9.57 8.80 1.3E-03 2.2E-03 0.59 0.539420 -1.71 
KANK1 D09 5.86 5.18 1.7E-02 2.7E-02 0.63 0.364501 -1.59 
KAT2B D10 8.53 8.71 2.7E-03 2.4E-03 1.13 0.603511 1.13 
KCNA4 D11 18.16 18.23 3.4E-06 3.3E-06 1.05 0.718505 1.05 
KIAA0195 D12 7.95 8.53 4.1E-03 2.7E-03 1.49 0.212327 1.49 
KLHL2 E01 8.06 8.27 3.7E-03 3.2E-03 1.15 0.434422 1.15 
KRAS E02 6.42 6.40 1.2E-02 1.2E-02 0.98 0.841916 -1.02 
LRBA E03 7.80 7.98 4.5E-03 4.0E-03 1.13 0.608517 1.13 
MAP1B E04 9.48 9.75 1.4E-03 1.2E-03 1.21 0.630339 1.21 
MAP3K10 E05 8.09 8.83 3.7E-03 2.2E-03 1.67 0.189699 1.67 
MGMT E06 7.58 7.67 5.2E-03 4.9E-03 1.07 0.638796 1.07 
NARF E07 6.40 6.29 1.2E-02 1.3E-02 0.93 0.605548 -1.08 
NLK E08 7.63 8.08 5.1E-03 3.7E-03 1.36 0.367233 1.36 
NMT2 E09 8.20 7.67 3.4E-03 4.9E-03 0.69 0.326794 -1.45 
NOTCH4 E10 13.32 13.69 9.8E-05 7.5E-05 1.30 0.020019 1.30 
NPEPPS E11 5.75 5.96 1.9E-02 1.6E-02 1.16 0.572568 1.16 
PLAG1 E12 17.56 15.56 5.2E-06 2.1E-05 0.25 0.142215 -3.98 
PLAU F01 16.33 18.32 1.2E-05 3.1E-06 3.97 0.237507 3.97 
PLCL2 F02 6.46 5.96 1.1E-02 1.6E-02 0.71 0.561881 -1.41 
PRKCD F03 8.67 9.75 2.4E-03 1.2E-03 2.11 0.219765 2.11 
PROX1 F04 20.49 18.99 6.8E-07 1.9E-06 0.35 0.383044 -2.82 
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PTPN11 F05 4.48 4.18 4.5E-02 5.5E-02 0.81 0.286405 -1.23 
PTPN22 F06 15.65 10.42 1.9E-05 7.3E-04 0.03 0.373580 -37.54 
RALA F07 5.00 5.36 3.1E-02 2.4E-02 1.28 0.219388 1.28 
RLF F08 7.14 7.47 7.1E-03 5.6E-03 1.26 0.183147 1.26 
RNF2 F09 6.38 6.85 1.2E-02 8.7E-03 1.39 0.250751 1.39 
SIRT1 F10 6.78 7.00 9.1E-03 7.8E-03 1.16 0.762576 1.16 
SLC2A1 F11 4.70 4.75 3.8E-02 3.7E-02 1.03 0.595572 1.03 
STAT1 F12 3.24 4.64 1.1E-01 4.0E-02 2.64 0.424496 2.64 
TANC2 G01 7.04 7.29 7.6E-03 6.4E-03 1.19 0.977385 1.19 
TBPL1 G02 7.45 7.80 5.7E-03 4.5E-03 1.27 0.451731 1.27 
TCERG1 G03 3.96 4.20 6.4E-02 5.4E-02 1.18 0.898740 1.18 
TCL1A G04 18.44 15.85 2.8E-06 1.7E-05 0.17 0.209868 -6.04 
TMEM131 G05 6.65 6.78 1.0E-02 9.1E-03 1.09 0.640466 1.09 
VSNL1 G06 17.34 20.03 6.0E-06 9.4E-07 6.45 0.226328 6.45 
YTHDC1 G07 5.73 5.91 1.9E-02 1.7E-02 1.13 0.826471 1.13 
ZFP36L1 G08 4.36 3.76 4.9E-02 7.4E-02 0.66 0.400925 -1.52 
ZFP36L2 G09 4.34 4.22 4.9E-02 5.4E-02 0.92 0.646202 -1.08 
ZNF180 G10 7.48 8.10 5.6E-03 3.7E-03 1.53 0.013637 1.53 
ZNF37A G11 6.39 7.38 1.2E-02 6.0E-03 1.98 0.068227 1.98 
ZNF83 G12 12.77 12.12 1.4E-04 2.2E-04 0.64 0.328636 -1.57 
ACTB H01 -1.79 -2.17 3.5E+00 4.5E+00 0.77 0.405856 -1.31 
B2M H02 -0.20 0.02 1.1E+00 9.9E-01 1.16 0.652129 1.16 
GAPDH H03 -1.23 -0.92 2.3E+00 1.9E+00 1.24 0.796353 1.24 
HPRT1 H04 4.14 3.78 5.7E-02 7.3E-02 0.78 0.484904 -1.28 
RPLP0 H05 -0.93 -0.71 1.9E+00 1.6E+00 1.16 0.418096 1.16 
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Figure 30. Overall gene regulation of miR-181a in HepG2 cells. HepG2 cells were transfected with 100nM miR-181a 
and total RNA extracted, reverse transcribed and underwent PCR. 84 genes were probed by real-time PCR and their fold 
change (test sample/control sample) plotted in a 3D graph. Both an increase and decrease in genes were detected, in 
contrast to only down-regulation in the case of mRNA targeting and degradation by miR-181a. This shows that miRNAs 
may regulate cellular activities at the translational instead of transcriptional level. BMPR2 gene expression levels 
showed a significant and consistent up-regulation in all three experimental repeats.  
 
 
Figure 31. Overall gene regulation of miR-181a inhibitor in HepG2 cells. HepG2 cells were transfected with 100nM 
miR-181a inhibitor and total RNA extracted, reverse transcribed and real-time RT PCR carried out in the microarray. 84 
genes were probed by real-time PCR and their fold change (test sample/control sample) plotted in a 3D graph. Similar to 
Figure 28, a combination of both up and down-regulation of genes is found when miR-181a was inhibited in HepG2 
cells. GATA6, NOTCH4 and ZNF180 were genes found to be significantly and consistently upregulated when miR-
181a was inhibited in HepG2 cells in all three experimental repeats. 
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Overall, we do see fold changes in most of the genes, both up and down regulated. The 
microarray is custom-made to probe for predicted genes targeted by miR-181a. Instead of 
downregulating most genes, we see a mix of both up and downregulation. This highly 
supports the general consensus that most human miRNAs affect gene expression at the 
translational level instead of causing mRNA degradation, since considerable amount of 
mRNA could still be detected. Not only that, but evidently from our previous transcription 
factor microarray study, the transfection of miR-181a causes a change in the expression 
levels or activities of transcription factors in HepG2 cells that are not known to be its 
direct targets. This in turn means that miRNAs are able to affect gene expression of 
mRNAs directly or indirectly, due to the vast interconnectedness of biological molecules 
in the cell. Therefore, in the analysis of this study, we broaden the scope of the term 
‘targets’ to include not just the possible direct targets, but the overall gene expression of 
HepG2 cells due to the direct or indirect effects of miR-181a and its inhibitor.  
We will discuss the effects of miR-181a and its inhibitor on genes that have shown 
significant up or down regulation. Only one gene showed a consistent and significant 
change in expression level when miR-181a was transfected into HepG2 cells. Bone 
morphogenetic protein receptor type 2 (BMPR2) mRNA expression level is shown to be 
significantly upregulated by a factor of 1.64 (p value=0.02) as compared to the control 
sample. The protein expressed by this gene is a serine/threonine receptor kinase that binds 
to bone morphogenetic proteins (BMPs) that leads to the transduction of cell signals 
involved in the SMAD, MAPK, NFκB, LIM domain kinase 1 (LIMK) and dynein, light 
chain, Tctex-type 1 (TCTEX) and v-src sarcoma viral oncogene homolog (SRC) 
signalling pathway [116]. As found earlier in our previous microarray pathway analysis, 
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SMAD2/3/4, NFκB, Elk-1/SRF and AP-1 transcription factors corresponding to SMAD, 
NFκB, and MAPK signalling pathways were found to be over-activated in HepG2 cells 
due to the transfection of miR-181a. The increased gene expression of BMPR2 due to 
miR-181a could have led to the overall activation of these pathways as its binding to 
BMPs aids in mediating these signal transductions. One interesting observation is that 
miR-181a also seemed to increase the gene expression of CDKN1β, albeit to an 
insignificant extent (p value= 0.54). It was previously noted that miR-181a slightly 
decreased the protein level of CDKN1β, although also insignificantly. This conflicting 
result could be due to the fact that miRNAs are known to regulate protein levels through 
mRNA translation rather than at the transcription level, therefore the level of CDKN1β 
mRNA did not reflect the corresponding protein level. Regardless, the two experiments 
have shown that the mean mRNA and protein levels of CDKN1β do not differ from that 
of their controls, therefore this gene might not play an important role in the downstream 
effects of miR-181a in HepG2 cells as much as E2F7.  
When miR-181a was inhibited in HepG2 cells, three genes showed a significant change in 
expression. GATA6, NOTCH4 and ZNF180 mRNA were found to increase by 1.89, 1.30 
and 1.53 times respectively (p values= 0.0438, 0.0200 and 0.0136). A study [78] has 
shown that miR-181a downregulates GATA6 protein in Hep3B cells and also binds to its 
mRNA. It also showed that the inhibition of miR-181a restored the expression of GATA6 
protein. Our studies on HepG2 cells show that inhibiting miR-181a significantly increases 
the expression of GATA6 mRNA. This may, or may not be through direct mRNA 
regulation. However, this supports the previous findings from other studies that miR-181a 
may target GATA6 mRNA. GATA6 is one of the regulators of hepatic cell differentiation. 
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It is also believed that the loss of expression of this gene leads to the ‘stemness’ of HpSC-
HCC, thereby giving hepatic cancer stem cells (CSCs) the ability to proliferate 
indefinitely. The increased gene expression of GATA6 due to the inhibition of miR-181a 
may lead to a reduction in ‘stemness’ of HpSC-HCC, thereby making it more vulnerable 
to HCC therapy.  
The inhibition of miR-181a caused a significant increase in NOTCH4 mRNA. While 
NOTCH1 is a relatively well-studied gene that when activated, causes apoptosis and 
inhibition of HCC proliferation, NOTCH4 is less understood. There are studies that have 
shown that NOTCH4 expression inhibits angiogenesis, endothelial sprouting and 
migration through collagen [117]. Other studies however, show that NOTCH4 is 
upregulated in neoplastic hepatocytes with respect to normal liver cells [118]. Its 
functional implication, however, is still not known. Similar to NOTCH4, ZNF180 is 
found to be significantly upregulated when miR-181a was inhibited in HepG2 cells from 
our microarray analysis. However, its role in HCC is not well understood. Its plays a role 
mainly in the physiological and pathological processes, but their mechanisms of actions 
are still not known [119].   
6.2.2 Section Conclusion 
 
Out of 84 genes probed, we obtained a significant upregulation in four such genes. Out the 
four genes, two of them are relatively well-studied and their functions understood, while 
the other two are comparatively more obscure. The transfection of miR-181a into HepG2 
cells caused an increase in BMPR2 mRNA expression level, whose protein when 
expressed is a receptor that mediates in the transduction of the SMAD, MAPK and NFκB 
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pathways. This observation was supported by our previous microarray study on cancer 
pathways, where an increase in expression and/or activities of all four transcription factors 
participating in these three pathways was observed. This could be one of the mechanisms 
in which miR-181a exerts its effect on in HepG2 cells. The increased expression of miR-
181a found in many HCC cases may enable liver cancer cells to activate these pathways 
due to the elevated BMPR2 gene expression level.  
The inhibition of miR-181a increased the expression level of GATA6. This gene aids in 
cellular differentiation, and its loss in expression has been found to lead to ‘stemness’, a 
quality of stem cells that makes them ‘immortal’ and with ‘unlimited growth potential’. 
The increased expression of GATA6 by inhibiting miR-181a could reduce this ‘stemness’ 
quality of liver cancer cells, which may be useful in liver cancer therapy.  
The two other genes found to be significantly upregulated when miR-181a was inhibited, 
NOTCH4 and ZNF180, are not well understood yet, and their role (if any) in cancers are 
also not well studied.  In this study, we may have identified one of the mechanisms in 
which miR-181a acts in activating the pathways involved in cancer, by the increased 
expression of BMPR2.  
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7. Conclusion  
 
HCC is currently one of the top cancers with the highest mortality rate. Popular treatment 
options include surgical resection or liver transplantation, radiotherapy and chemotherapy, 
TACE, etc. While surgical resection and liver transplantation are effective in eradicating 
liver cancer in patients at the early stages of the disease, patients diagnosed at the mid or 
terminal stages usually have very low survival rates under TACE, chemotherapy or 
radiotherapy. These treatment methods cause unwanted side effects and therefore have 
limited effectiveness. MiRNAs have been shown to be able to regulate many cellular 
processes, including proliferation, differentiation, angiogenesis, cell development, etc. Its 
main mode of regulation is through the binding of multiple target mRNAs, leading to the 
translational inhibition of the mRNAs into their proteins. Therefore, miRNAs are able to 
affect the protein profile of a cell. In this study, we investigated the role of miR-181a in 
HCC. MiR-181a has been shown to be upregulated in HCC and HpSC-HCC, and found to 
be involved in cellular differentiation. Its role in cancer, however, has yet to be 
investigated upon. In the first part of this project, we aim to elucidate the overall effects 
miR-181a exerts in HepG2 cells. Particularly, we made use of LC-MS/MS technology in 
identifying and quantifying proteins dysregulated when miR-181a was overexpressed or 
inhibited in HepG2 cells. We chose to study the protein profile because proteins are 
known to be the ‘molecular machines’ of cells, and cellular phenotype, whether diseased 
or healthy, is largely due to the cellular protein expression levels. From the LC-MS/MS 
analysis, we found that the overexpression of miR-181a in HepG2 cells led to a significant 
increase in NPM1 protein, while its inhibition lowered the expression levels of Hsp-90β 
protein. NPM1 is found in many human cancers including those of the stomach, prostate, 
129 
 
colon, bladder, and liver. NPM1 overexpression in tumour cells was also found to lead to 
an increased proliferation and inhibition of apoptosis. Inhibiting miR-181a, on the other 
hand, led to a decrease in Hsp-90β, a chaperone usually highly expressed by cancer cells 
to help protect and ensure proper folding and functioning of its proteins. The decrease in 
Hsp-90β due to the inhibition of miR-181a may lead to a reduction in protection of cancer 
cells. These initial results from the protein profile analysis of HepG2 cells may suggest 
that miR-181a acts as an oncogene while its inhibition could produce tumour suppressing 
effects. The expression levels of these two proteins in HepG2 cells transfected with miR-
181a and its inhibitor were subsequently validated with a Western blot analysis, and are in 
line with the results obtained from the LC-MS/MS. 
Based on results from the protein profile analysis, we infer that miR-181a may have 
effects in important cancer-related pathways like cell growth. A cell viability assay shows 
that miR-181a causes a significant increase in HepG2 cell viability while inhibiting it 
significantly reduces viability by about 20%. As cell cycle is closely related to cell 
viability, we also employed flow cytometry to study if cell cycle is affected by miR-181a. 
While miR-181a itself did not cause a significant change in cell cycle, inhibiting it caused 
a significant decrease in proportion of cells in the S phase, while at the same time, 
increasing the proportion of cells in the G1 phase. Inhibiting miR-181a, therefore, may 
reduce HepG2 cell viability by delaying cell cycle entry. From these studies, our results 
suggest that miR-181a causes an increase in cell viability, possibly through exerting some 
effect in the cell cycle as one of the mechanisms and the upregulation of proliferative 
proteins as another.  
130 
 
We next delved into the molecular level and investigated the direct mRNA targets of miR-
181a. Because there can be many potential targets, we made use of bioinformatics to aid 
in target prediction. Among the targets predicted, CDKN1β and E2F7 were chosen for 
further study because they are both important cell cycle genes, and as shown in our earlier 
study, miR-181a may have an effect on the cell cycle. We first tested out the 
miRNA:mRNA interactions in vitro using SPR technology. The predicted binding sites in 
the 3’UTRs of the mRNAs were synthesized and localized onto the SPR platform while 
miR-181a was injected as the flow through. SPR results show a positive binding between 
miR-181a and the 3’UTRs of both CDKN1β and E2F7, with a higher affinity and stronger 
binding between miR-181a and the 3’UTR of CDKN1β (lower dissociation constant). 
After a positive validation of interaction in vitro, we proceeded to test for any binding in 
vivo via luciferase assay. The 3’UTRs of both CDKN1β and E2F7 were cloned into a duo-
luciferase reporter plasmid and co-transfected along with miR-181a into HepG2 cells. A 
significantly lower luciferase activity was detected in both reporter plasmids as compared 
to the control plasmid, suggesting a positive binding of miR-181a to the 3’UTRs of both 
CDKN1β and E2F7 in vivo. In vivo, however, it seems that the binding between miR-181a 
and E2F7 is stronger than with CDKN1β, because of the lower luciferase activity detected. 
It could be due to the various enzymes and molecular machinery present in the cells, as 
well as the more extensive sequence complementarity that favour the binding of miR-
181a to the 3’UTR of E2F7. The positive interaction between miR-181a and the 3’UTRs 
of both mRNAs led us to further study whether the binding may cause a decrease in their 
respective protein expressions. A Western blot study showed that the protein levels of 
CDKN1β and E2F7 were lowered, with E2F7 expressed at a much lower level than the 
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control sample as compared to CDKN1β, when HepG2 cells were transfected with miR-
181a. This supports the notion that the binding between miR-181a and E2F7 may have 
been stronger than that of miR-181a and CDKN1β. 
We next investigated the effects miR-181a has on important transcription factors involved 
in cancer-related pathways, because ultimately, we are interested to get an overview of the 
effects of miR-181a in cancer. The transcription factors included in the study may not be 
direct targets of the miRNA. Using a microarray analysis, we studied ten different cancer 
pathways and their transcription factors. What was interesting in our findings is that the 
SMAD, MAPK and NFκB signalling pathways were found to be activated, with a 
significant activation in the MAPK/JNK pathway when HepG2 cells were transfected 
with miR-181a. The significant activation of AP-1 transcription factor in the MAPK/JNK 
pathway positively regulates the cell cycle and antagonizes apoptosis in liver tumours, 
possibly leading to an increase in cancer cell viability in the process. Inhibiting miR-181a, 
on the other hand, overall activates most tumour suppressing pathways and inactivates 
tumour-promoting ones. Hypoxia was found to be significantly reduced while SMAD was 
significantly activated. Contradicting pathways were still activated though, with the 
increase in activity of the NFκB pathway. Overall, it is the balance of effects of these 
pathways that leads to the phenotype of the cell.  
Lastly, we also employed a microarray analysis to study the possible direct targets of 
miR-181a. This differs from the previous methods because of its much higher throughput. 
However, one should note that, because miRNAs are generally known to affect gene 
expression at the translational level, the use of this array would only be useful for miRNA 
targeting via mRNA degradation. However, we also know that miRNAs exert their effect 
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not just through their direct targets but also indirectly on other genes-- not a surprise due 
to the interconnectedness of the components of a cell. Therefore, the microarray analysis 
was carried out as an overall gene expression analysis, instead of focusing on 
downregulation of target mRNAs. Among 84 genes probed, two particular genes garnered 
interest. A significant increase in BMPR2 mRNA expression was seen in HepG2 cells 
transfected with miR-181a. The gene product is a receptor that mediates the SMAD, 
MAPK and NFκB signalling pathways, which are important pathways in cancer. 
Incidentally, these pathways were seen to be activated when HepG2 cells were transfected 
with miR-181a (as shown in the previous microarray analysis on cancer-pathways). 
MAPK and NFκB are activated in most cancers, while the activation of SMAD pathway 
has an opposing tumour suppressing effect. The balance of these activated pathways may 
have led to an overall increase in cell viability of HepG2 cells when transfected with miR-
181a. Inhibiting miR-181a, however, significantly increased the gene expression of 
GATA6. GATA6 is involved in aiding cellular differentiation, and the reduced expression 
of this gene encourages ‘stemness’, allowing cells to proliferate indefinitely. Inhibiting 
miR-181a has been shown to reduce cell viability, and one such mechanism may be due to 
the increase in GATA6, which decreases the chances of forming cancer stem cells in HCC. 
In conclusion, we find that miR-181a has an overall oncogenetic effect in HepG2 cells. It 
increases HepG2 cell viability, possibly through the activation of a myriad of cancer-
causing pathways (ie. MAPK/JNK). It also significantly increases gene expression of 
BMPR2 that mediates the activation of these pathways. Not only that, but it is found to 
bind to and downregulate CDKN1β and E2F7 mRNAs and proteins respectively, which 
both play a part in the negative regulation of the cell cycle.  Inhibiting miR-181a, on the 
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other hand, reduces HepG2 cell viability, possibly by activating tumour suppressing 
networks (ie. SMAD) and deactivating tumour causing pathways (ie. HIF). It also causes 
a significant delay in cell cycle progression, perhaps by the slight reduction of activity of 
E2F proteins. It decreases the expression of Hsp-90β protein, reducing the inherent 
protection of HepG2 cells. The 20% decrease in viability measured may have been limited 
though, due to the simultaneous activation of tumour-causing pathways like NFκB. Direct 
targeting of this pathway using siRNAs, along with the inhibition of miR-181a, could 
potentially increase its therapeutic effect in HCC. A suggested role of miR-181a in 
HepG2 cells is illustrated in Figure 30. 
 
Figure 32. Illustration of suggested pathways affected by miR-181a in HepG2 cells. Overall, miR-181a activates 
many proteins and pathways involved in cell cycle/proliferation and angiogenesis, which are crucial pathways also 
activated in most cancers. Inhibiting this miRNA abolishes this and even may inhibit these cancer-promoting pathways 
from progression. 
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8. Future Work 
 
Our data has shown that inhibiting miR-181a in HepG2 cells produces a therapeutic effect, 
albeit limited. We have also elucidated certain important proteins and pathways activated 
by inhibiting miR-181a, mostly tumour suppressing but a few other contradicting 
oncogenetic pathways. Because we are interested in HCC therapy, the use of miR-181a 
inhibitor with siRNAs may be a viable method in causing a further decrease in cancer cell 
viability. The problem with cancers is that many proteins and pathways tend to be 
dysregulated simultaneously, such that the use of siRNAs alone that target specific 
pathways does not cause total eradication of the cancer. MiRNAs, therefore, serve as a 
good vehicle for targeting multiple pathways at the same time. However, its main setback 
is the non-specificity of its targeting, as seen in our project, such that it is able to cause 
activation in both tumour cell growth and apoptosis pathways. A balance of both the use 
of miRNAs and siRNAs, could therefore aid in targeting multiple pathways yet prevent 
the activation of unwanted, tumour-promoting pathways. A co-transfection of miR-181a 
inhibitor with NFκB siRNA into HepG2 cells may be one area of study that could 
potentially lead to a further decrease of cancer viability.  
As in the case of siRNAs that causes a knock down in gene expression, small activating 
RNAs (saRNAs) cause an increase in gene transcription. This may be used along with 
miR-181a inhibitor in now activating genes that are tumour suppressing. Genes like p53, 
which are slightly upregulated due to miR-181a inhibition, may be further upregulated 
when co-transfected with the saRNA for p53.  
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Other than the use of miRNAs with siRNAs or saRNAs, many different combinations of 
therapy could be used to further improve on the results. MiRNAs with drugs, as shown in 
our study, may cause an additive decrease in cancer cell viability, proving that miRNAs 
may be used in tandem with chemotherapy to produce an enhanced therapeutic effect. 
This may mean that the dosage of drugs used in treatment need not be as high as before, 
therefore minimizing unwanted harmful side effects in patients. Of course, the side effects 
caused by miRNAs would have to be investigated upon prior to that. MiRNAs are 
endogenous molecules by nature, therefore their use in patient therapies are likely to be 
better received than the use of chemicals or radiotherapy.   
Other miRNAs may also be used in HCC therapy, or used alongside miR-181a inhibitor. 
However, because a single miRNA alone is able to cause a massive change in cellular 
profile, the combination of miRNAs may complicate the cellular network such that there 
are too many variables changing at the same time. That saying, a combination of miRNAs 
in therapy may theoretically work; however the study of underlying mechanisms may not 
be as simple as the other methods proposed earlier.   
Apart from the use of miR-181a inhibitor on HepG2 cells, it may also be used to study 
other liver cancer cell lines like Hep3B, HuH7 or even HepG2.215. Because HCC is a 
cancer of heterogeneous background, the use of miR-181a inhibitor in HepG2 cells may 
cause a different effect in other cell lines and/or in vivo in human patients. Hence, a more 
thorough investigation is required to obtain a broader picture of the function of miR-181a 
inhibitor in HCC. 
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In these potential studies, the use of the LC-MS/MS may be very useful in investigating 
the proteins profile due to treatment. Not only can this technology be used in miRNA 
studies, it may also be used in studying cancer cells treated with drugs, radiation, siRNAs, 
or a combination of these. Through the use of the LC-MS/MS, we are able to gain an 
understanding of important proteins perturbed by these treatments. Further improvements 
can then be made upon the investigations once the molecular mechanisms are elucidated, 
and this cycle of testing and understanding is repeated until an optimal treatment method 
is developed.  
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Additional Data for miR-181a in Target Array Analysis 
3D Profile plot values 
3D 
Profile A B C D E F G H 
1 1.19 1.26 1.57 0.10 1.09 2.94 1.23 0.71 
2 1.37 0.35 1.73 0.15 1.20 0.52 0.93 1.17 
3 0.71 1.59 0.53 1.93 1.26 2.29 0.69 1.28 
4 5.87 1.37 1.06 0.90 1.21 0.29 0.53 0.73 
5 1.23 2.85 0.99 1.18 1.62 1.04 1.26 1.28 
6 1.47 1.17 1.49 1.17 2.34 0.08 28.34   
7 1.32 0.10 0.33 0.66 0.81 1.12 1.11   
8 0.91 1.03 0.77 1.20 1.21 1.13 0.67   
9 1.27 2.69 1.13 0.59 0.69 1.26 0.73   
10 1.64 1.06 3.05 0.97 1.38 1.18 1.23   
11 0.93 0.69 1.46 0.89 1.06 1.09 1.65   
12 1.27 2.14 1.27 1.36 0.41 3.75 1.09   
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Volcano Plot 
 
 
Additional Data for miR-181a inhibitor in Target Array Analysis 
3D Profile plot values 
3D 
Profile A B C D E F G H 
1 1.33 1.05 1.08 0.25 1.15 3.97 1.19 0.77 
2 1.22 0.30 1.47 1.43 0.98 0.71 1.27 1.16 
3 0.85 1.47 0.44 1.31 1.13 2.11 1.18 1.24 
4 1.60 2.35 0.62 1.20 1.21 0.35 0.17 0.78 
5 1.09 2.91 1.42 1.25 1.67 0.81 1.09 1.16 
6 1.34 0.81 1.26 1.10 1.07 0.03 6.45   
7 1.25 0.05 0.47 0.58 0.93 1.28 1.13   
8 1.00 0.90 0.84 0.59 1.36 1.26 0.66   
9 0.98 1.04 0.88 0.63 0.69 1.39 0.92   
10 1.66 1.04 3.26 1.13 1.30 1.16 1.53   
11 0.77 0.54 1.89 1.05 1.16 1.03 1.98   
12 1.00 1.53 1.49 1.49 0.25 2.64 0.64   
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